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ABSTRACT  
BRCA1 is a tumour suppressor protein involved in many important pathways such as DNA 
repair, cell cycle regulation, apoptosis, spindle formation and telomere regulation. BRCA1 
germline mutations confer the highest risk to breast cancer. Furthermore, reduced levels of 
BRCA1 are also observed in many sporadic breast cancers. Despite the obvious 
importance of BRCA1, genetic screening is usually restricted to BRCA1 exons and intron-
exon boundaries. The possibility that mutations exist outside these regions has not been 
fully investigated and may be responsible for breast cancer predisposition in a subset of 
cases. It is becoming increasingly clear that long-range transcriptional control is an 
important mechanism for regulating gene expression. In support of this concept several 
human diseases, including breast cancer, have been associated with dysregulation in 
long-range control elements. Currently, only two papers have studied long-range 
regulation of BRCA1. In 2005, Wardrop et al identified a putative enhancer and silencer 
element within BRCA1 intron 2, 5kb downstream of the BRCA1 promoter [1]. Then in 
2008, Tan-Wong et al identified distal regulatory elements located within the BRCA1 
terminator region [2]. However, identifying regulatory elements outside BRCA1 and 
determining whether mutations in these elements contribute to BRCA1 deregulation is still 
relatively unexplored. This project aims to expand the repertoire of BRCA1 long-range 
regulatory elements using gene conformation techniques such as chromosome 
conformation capture (3C) and its derivatives. The project hypothesis is that defects in 
long-range regulatory elements of BRCA1 transcription contribute to breast cancer 
predisposition.  
Using a candidate 3C approach, we identified a potential cis-regulatory element, called 
PRE1, located approximately 157 kb downstream of the BRCA1 promoter. The frequency 
of this interaction increased with estrogen stimulation, suggesting that chromatin looping is 
associated with BRCA1 transcription. Bioinformatic analysis showed that this element is 
flanked by DNase hypersensitivity and histone marks, which suggests it is an enhancer of 
BRCA1. This was confirmed by luciferase reporter assays which demonstrated that PRE1 
acts as a weak enhancer, resulting in a 10% increase in BRCA1 promoter activity. Using 
ChIP we showed that the TF c-Myc binds to both PRE1 and the BRCA1 promoter, 
however depletion of c-Myc RNA levels did not alter PRE1s enhancer activity. Using a 
genome-wide circular-3C (4C) approach, we identified a potential trans-regulatory silencer 
element located 5kb upstream of G2E3 on chromosome 14. This trans-interaction was 
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validated by 3C in MCF7 cells, which suggests that the interaction is potentially functional. 
Consistent with this, bioinformatic analysis showed that this element, called PRE2, is 
flanked by DNase hypersensitivity and strong histone marks indicative of a silencer. 
Notably, luciferase assays showed that a modified version of PRE2 could repress BRCA1 
promoter activity, resulting in a 3-fold decrease in activity. This research project has 
provided the first important steps to fully understanding the molecular pathways underlying 
BRCA1 regulation. The identification and characterisation of novel long-range control 
elements of breast cancer genes will immediately improve genetic screening procedures, 
and permit the development of more specific therapeutic approaches. 
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2 INTRODUCTION 
2.1 Breast Cancer 
Breast cancer is a heterogeneous disease. It can be characterised by resistance to 
apoptosis, increased angiogenesis, limitless replicative potential, activating invasion and in 
certain cases, metastasis [3]. Breast cancer usually starts when a single cell acquires a 
series of mutations, which collectively leads to abnormal gene expression, then in 
combination with other epigenetic alterations drives the development of cancer. Breast 
tissue comprises of connective tissues, blood vessels, lymph vessels and mammary ducts 
consisting of the basement membrane, a layer of luminal epithelial and myoepithelial cells 
(Figure 1). The basement membrane acts as anchorage for epithelial cells, separating the 
epithelial layer from the loose connective tissue beneath and functions as a barrier to 
prevent metastasized cell from invading tissues. During lactation, the luminal epithelial 
layer synthesizes milk proteins and the myoepithelial layer contracts under the stimulation 
of oxytocin to secrete milk [4, 5]. However, in cases of in situ carcinomas, myoepithelial 
cell number decreases due to epigenetic and phenotypic alterations and the basement 
membrane starts to degrade [6]. Simultaneously, stromal fibroblasts, lymphocytes, 
myofibroblasts and endothelial cell numbers increase drastically [7]. In invasive 
carcinomas, loss of the basement membrane and myoepithelial cells occurs [6, 8]. If left 
untreated, a single cell or a group of cells from the tumour can break off and travel to other 
parts of the body via the lymphatic system and/or the blood stream. Once mobile, these 
breast cancer cells can penetrate the walls of the lymph and/or blood vessels of other 
organs to form new tumours [9]. The translocation of cancer cells to other parts of the body 
is known as metastasis.  
2.1.1 Incidence 
The incidence of breast cancer has increased dramatically in the last 20 years. In 
Australia, breast cancer incidence rates have risen by over 30% to become the most 
common malignancy among Australian women [10]. One in nine women are estimated to 
be diagnosed with breast cancer by age of 85 [11]. The incidence of breast cancer can be 
associated with several risk factors including age, prolonged hormone therapy, obesity and 
strong family history [12-14]. Although the number of women and men diagnosed with 
breast cancer continues to increase, the rate of mortality in recent years has declined 
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reflecting largely upon the success of breast cancer awareness campaigns and mass 
screening. 
 
 
 
 
Figure 1. Breast cancer progression in human mammary ducts. Adapted from [6] 
 
2.1.2 Genetic Susceptibility  
Whilst the majority of breast cancers do not have a clear or known hereditary component, 
it is known that family history is one of the strongest risk factors. Inherited mutations in 
breast cancer susceptibility genes significantly increase breast cancer risk [15]. Genetic 
variants associated with breast cancer can be classified into three broad categories: high-
risk variants, rare moderate-risk variants and common low-risk variants (Figure 2). High-
risk variants are found in the major breast cancer genes, such as BRCA1 and BRCA2 [16], 
have a low allele frequency of approximately 0.1%, but confer a high relative risk (usually 
above 10). Moderate-penetrance mutations such as those found in ATM and CHEK2, are 
associated with intermediate risk (relative risk between 2–5; Figure 2) and low-penetrance 
polymorphisms, which are common in the population and associated with a relatively small 
risk (relative risk <1.5; Figure 2). High and moderate penetrance mutations are estimated 
to account for ~25% of total familial risk [17]. The remainder of familial risk is likely to be 
explained by a polygenic model involving a combination of several low-penetrance 
variants. 
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Figure 2. High, moderate and low-risk variants in genes/loci associated with breast 
cancer and their corresponding relative risk and risk allele frequency in breast 
cancer [18].  
 
2.2 BReastCAncer 1 (BRCA1) Susceptibility Protein 
2.2.1 BRCA1 Structure 
BRCA1 is a large 1,863 amino acid phosphoprotein, with a molecular weight of 220 kDa, 
and contains domains that exhibit both enzymatic activity and protein binding sites (Figure 
3). BRCA1 contains an N-terminal ring domain which exhibits E3 ubiquitin ligase activity 
and two nuclear export signals recognised by nuclear export receptor exportin 1 [19-21]. 
The LXCXE motif following the ring domain is a retinoblastoma (RB) binding domain and 
disruption of this motif abolishes BRCA1’s repression of RB genes [22]. Next, are two 
nuclear localisation signals (NLS) involved in BRCA1’s nuclear import via the importin 
receptor pathway [23]. Notably, in BRCA1 splice variants that lack the NLS, BRCA1 can 
still enter the nucleus via its ring domain interaction with the chaperone protein BRCA1-
associated RING domain protein 1 (BARD1) [24]. BRCA1 also contain a transcriptional 
activation domain (TAD) in its C-terminus (aa 1560 to 1863) [25]. This domain consists of 
two BRCT (BRCA1Carboxy-Terminal) domains that interact with the BRCT family of 
proteins such as, BARD1. [26, 27]. A second transcriptional activation domain, activation 
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domain 1 (AD1) spanning amino acid 1,293-1,560, can either synergistically activate 
transcription with the TAD or independently activate transcription [28]. Interestingly, 
transcriptional activation of the AD1 by BRCA1 depends on interaction with Jun family 
proteins [29]. A large variety of proteins partners can bind to BRCA1 at different sites 
thereby linking BRCA1 to a diverse range of functions (Figure 3). In some cases, a single 
protein partner can bind at more than one BRCA1 site, for example estrogen receptor (ER-
α; aa 1-100 and aa 101-200), c-Myc (aa 175-303 and aa 443 - 511) and p53 (aa 224-500, 
aa 1760-1863 and aa 772 -1292) [30-32].  
 
 
 
Figure 3. Protein-interacting domains of BRCA1. Summarised from [19-22, 25, 28, 33] 
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2.2.2 BRCA1 Post-translational Modifications  
 
Like many other proteins, BRCA1 can undergo post-translational modifications, such as 
methylation, ubiquitination and phosphorylation. Firstly, methylation status modulates 
BRCA1-dependent transcriptional control by altering the ability of BRCA1 to bind to TFs 
and promoters. For example, hypermethylation of BRCA1 decreases dimerization to 
Specificity Protein 1 (Sp1), thereby allowing binding of Sp1 to the insulin-like growth factor-
I receptor (IGF-1R) promoter [34]. This contributes to the overexpression of IGF-1R in 
breast cancer [34]. Conversely, hypomethylated BRCA1 mediates Sp1 binding to the 
promoter of AP endonuclease (APEX), a protein involved in base excision repair [35]. 
Secondly, ubiquitination of BRCA1 occurring at different positions results in different 
effects. Ubiquitination at Lys6 stabilizes the BRCA1-BARD1 complex as well as activates 
its E3 ligase activity [36]. However, ubiquitination at Lys48 targets BRCA1 for degradation 
via the ubiquitin/proteasome mediated pathway [37Blagosklonny et al 1999 , 38]. Lastly, 
phosphorylation of BRCA1 is required for DNA repair and promotes G2/M transition of the 
cell cycle [39]. 
2.2.3 BRCA1 Function 
BRCA1 is involved in many crucial pathways such as cell cycle regulation, DNA repair, 
apoptosis, spindle formation and telomere regulation (reviewed in [40]). BRCA1 controls 
G1 arrest through coupling with hyperphosphorylated RB [41]. This BRCA1/RB complex 
inhibits transcription, leading to G1 arrest. BRCA1 also promotes G1 arrest by repressing 
c-Myc, an activator for Cell Division Cycle 25 Homolog A (CDC25A) [42]. CDC25A is a 
protein required for G1 to S phase transition [43, 44]. Furthermore, BRCA1 induces p21, 
which suppresses entry into S phase [45]. BRCA1 has also been speculated to promote 
transcription of RING1- and YY1-binding protein (RYBP) since BRCA1 binds to the RYBP 
promoter [46]. RYBP is known to induce G1 arrest and stabilize p53 [47]. BRCA1 has also 
been implicated in S, M and G2 phase checkpoint [39, 48-50]. In addition, BRCA1 is 
involved in the apoptotic pathway, where it activates p53 expression and stabilises p53 
protein levels [51]. 
 
BRCA1 also plays an important role in DNA repair pathways for both chromosomal and 
mitochondrial DNA repair [52-54]. BRCA1 and MRE11/RAD50/NBS1 (MRN) complex are 
part of the BRCA1-associated genome surveillance complex [55, 56]. Besides MRN, the 
BRCT domain of BRCA1 can also bind double stranded breaks in DNA, which suggests 
that BRCA1 itself might recognise these types of breaks [57, 58]. Recent data suggests 
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BRCA1 is also involved in another DNA repair pathway called Base Excision Repair (BER) 
[59]. Furthermore, BRCA1 directly inhibits centrosome-dependant microtubule nucleation 
[60-63]. In addition BRCA1 inhibits telomerase activity, regulating telomere length [64]-[65, 
66]. More recent studies also suggest that BRCA1 inhibits cell motility and promotes 
detoxification [67, 68]. 
2.2.4 BRCA1 and Breast Cancer 
Loss or reduction of functional BRCA1 levels observed in breast cancer can be due to 
absence of full length BRCA1 through protein truncation, loss or decreased BRCA1 
expression [69] or elevated protein degradation [37]. Unbound BRCA1 is tagged for 
proteasome degradation by the ubiquitin ligase, HECT domain and RCC1-like domain-
containing protein 2 (HERC2) [37]. Since immunohistochemical staining was able to detect 
HERC2 in approximately 50% of breast tumours, and half of these cases exhibited inverse 
correlation with BRCA1, overexpression of HERC2 in some breast tumours may explain 
reduced BRCA1 levels. Furthermore, BARD1 interaction with BRCA1 inhibits HERC2-
mediated BRCA1 ubiquitination [70]. In addition, down-regulation of full length BARD1, 
accompanied by over-expression of BARD1 isoforms are detected in breast cancer, 
suggesting that reduced levels of BARD1 and up-regulation of BARD1 isoforms might 
contribute to increased BRCA1 degradation as well [70]. Collectively, dysregulation of both 
HERC2 and BARD1 might contribute to BRCA1 down-regulation by elevating BRCA1 
degradation in breast cancer. 
2.3 The BRCA1 Gene 
2.3.1 BRCA1 structure 
BRCA1 consists of 24 exons and spans a length of 81,189 bp on chromosome 17q21 
(Figure 4). The largest exon of BRCA1 is exon 11. BRCA1 is positioned between NBR2 
(Neighbour of BRCA1 gene 2) and RND2 (Rho family GTPase 2) [71]. Detection of 
BRCA1 with different protein sizes, 210, 184, 160, 135 and 85 kDa suggests that different 
isoforms might have different functions, however, the function of these isoforms are still 
unclear [72].  
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Previously, it was known that at least 2 of the BRCA1 isoforms are regulated through 
alternative splicing [73, 74]. BRCA1-∆11 is the result of exclusion of exon 11 by in-frame 
splicing [75]. BRCA1-∆11 expressing mice embryos die at embryonic day 8.5 as compared 
to BRCA1 null embryos which die at embryonic day 6.5 suggesting that BRCA1-∆11 only 
partially compensates for BRCA1 full length function during early embryogenesis [76]. This 
is not surprising as exon 11 is the largest exon of BRCA1 and encodes over 60% of the 
protein. Therefore the loss of exon 11 would result in exclusion of many crucial protein-
binding sites although the N-terminal and C-terminal remains similar to the full-length 
protein. In addition, BRCA1-IRIS has a termination point 34 triplets into intron 11 due to 
alternative splicing [74]. BRCA1-IRIS does not interact with BARD1 in vivo or in vitro, 
unlike BRCA1 full-length protein [74]. Currently, even more splice isoforms have been 
identified by qRT-PCR and verified by Western Blotting [77]. Interestingly, certain BRCA1 
isoforms can only be found in breast cancer cell line, ZR-75-30 suggesting that 
identification of cancer–specific isoforms might improve diagnosis for breast cancer [77]. 
 
Figure 4. BRCA1 and surrounding genes. BRCA1 is positioned between NBR2 and 
RND2. The grey boxes represent exons. Adapted from [78]. The bidirectional promoter 
includes BRCA1 exon 1a [1]. 
2.3.2 BRCA1 promoter 
The BRCA1 promoter consists of α and β promoters, which drives transcription of exon 1a 
and exon 1b respectively. Both promoters are responsive to estrogen (E2) [79]. Promoter 
α is a bi-directional promoter shared between BRCA1 and neighbouring NBR2 [80]. Only 
promoter α drives transcription in normal mammary cells [81], however, there is evidence 
to suggest a partial switch to promoter β in breast cancer which results in a decrease in 
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BRCA1 expression [82]. The BRCA1 promoter α is the most commonly studied promoter 
of the two and it consists of multiple TF binding sites, which can drive or repress 
transcription (Figure 5) [83, 84]. Promoter α contains two E boxes upstream of the positive 
regulatory region (PRR) which consists of three E-Twenty Six (ETS) elements known as 
the RIBS element and a cyclic-AMP response element (CRE) [85]. The promoter also 
contains a CAAT box, Sp1 and activator protein 1 (AP1) binding sites and houses a 
composite repressor element known as UP which consists of an E2F site and a GA 
binding protein α/β (GABPα/β) binding site. Furthermore an E2F site is located between 
the UP site and the BRCA1 transcriptional start site. Some of these sites such as CRE and 
Sp1 can be methylated [86-89]. 
2.3.3 BRCA1 and Breast Cancer  
BRCA1 mutations can confer risks of up to 71.4% to breast cancer by the age of 70 [90]. 
BRCA1 mutations such as splice sites mutations, nonsense mutations, frame-shift 
mutations or missense mutations can result in abnormal length of mRNA, premature 
termination during RNA synthesis, loss/decreased transcription or change of codons that 
ultimately lead to production of non-functional BRCA1 or down-regulation of BRCA1 [69, 
91-93]. In contrast, there are also some silent mutations that do not result in a change of 
codons therefore such mutations do not affect BRCA1 functionality [94]. Tumours from 
patients with a germline mutation of BRCA1 have a distinct pathology. BRCA1 mutation 
type tumours arise at a younger age and commonly display pushing margins, lymphocytic 
infiltration and are usually of higher grade than other tumours types [95, 96]. In addition, 
they often display aneuploidy [97], have a higher S-phase fraction, higher mitotic counts 
and exhibit a higher degree of nuclear pleomorphism [98] and are frequently associated 
with the axillary lymph node [99]. BRCA1 type tumours are also usually triple negative for 
progesterone (PR), ER and human epidermal growth factor 2 (HER2) [100, 101].  
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Figure 5. Schematic of transcription factor (TF) binding sites within the 
BRCA1/NBR2 bi-directional promoter. Blue arrow depicts the minimal BRCA1 promoter 
region. Green arrows represent transcriptional activation and red arrows represent 
transcriptional repression. White arrows represent the effect of the TF can be either 
repressive or activating, depending on the isoform. Red line with bar head represents an 
inhibitory effect (Figure not drawn to scale) [85, 102-104]. 
 
2.4  Regulation of BRCA1 
2.4.1  Promoter Methylation 
The BRCA1 promoter region contains a number of CpG islands, which can be highly 
methylated in breast cancer cells [105]. Several studies have now shown that promoter 
hyper-methylation is associated with histone hypoacetylation, chromatin condensation and 
transcription inhibition [106-108]. Hypoacetylation of histones inhibits unwinding of 
chromatin, therefore TFs are unable to reach the BRCA1 promoter and transcription is 
repressed [106-108]. Furthermore, methyl-binding protein MeCP2, which is part of a 
repressor complex, can bind to methylated CpG islands on BRCA1 promoter [109], thus 
silencing it further. Hypermethylation has also been suggested to be partly responsible for 
the switch between BRCA1 promoter α to β in breast cancer [82]. However, only a small 
percentage (10-20%) of breast cancers have BRCA1 promoter hypermethylation [87], 
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suggesting that other regulatory mechanisms are involved. In addition to promoter 
methylation, BRCA1 expression is also regulated by TFs. 
2.4.2  Transcriptional Regulation  
As mentioned previously, the BRCA1 promoter α contains multiple TF binding sites (Figure 
5). There are a number of TFs that can activate BRCA1 transcription, including c-Myc and 
MyoD which bind Enhancer Box sequences (E boxes) located upstream of the BRCA1 
transcription start site (TSS) [84, 110]. In contrast, the BRCA1 promoter region also 
contains negative regulatory elements such as an UP site consisting of two repressive 
regions, the E2F site and a GABPα/β binding site [85]. This GABPα/β binding region forms 
a stronger composite repressor element when coupled with the E2F site [85]. Interesting, 
although GABPα/β activates transcription when bound to the PRR, it exerts a repressive 
effect when bound to the UP site [85]. Therefore the effect of the TF depends on the 
binding site on the promoter. However, other studies have shown that the effect of a 
binding site also depends on the TF. For example, E2F1 activates transcription when 
bound to E2F sites on the BRCA1 promoter however E2F-6 is repressive [85, 111].  
 
Numerous other TF binding sites such as the CRE (cyclic-AMP response element), Sp1 
and AP1 binding sites in the promoter demonstrates that BRCA1 transcription can be 
controlled by a wide array of TFs (Figure 4). For example, HMGA (High Mobility Group A) 
is a repressor of the BRCA1 promoter and often over-expressed in breast carcinomas 
[112]. Id4 (inhibitor of DNA binding-4) is another repressor involved in inhibiting GABPα/β 
activated BRCA1 transcription [113, 114]. Furthermore ETS-2 (E-twenty six-2) represses 
BRCA1 transcription through competitive binding against GABPα/β at the PRR. Clearly, 
BRCA1 transcription is a complex process, and reduced expression of BRCA1 could be a 
result of de-regulation of any or all of these proteins.  
2.4.3 Post-transcriptional regulation 
BRCA1 has also been shown to be post-transcriptionally regulated. In 2007, Saunus et al, 
discovered that the RNA binding protein HuR can bind BRCA1 mRNA without significantly 
changing BRCA1 mRNA stability, however it does decrease BRCA1 protein levels. Hence 
translation would be inhibited in the case of HuR bound BRCA1 mRNA [115]. In addition to 
RNA-binding proteins, BRCA1 is most likely regulated post-transcriptionally by other 
factors that can affect translation such as secondary structure stability of the mRNA 
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transcript. In breast tumours, there is a partial switch of transcription from exon 1a to exon 
1b. Exon 1b transcripts have lower translation efficiency due to its unstable secondary 
structure. Furthermore micro RNA, miR-146a and miR-146b-5p, have recently been shown 
to down-regulate BRCA1 by binding to the 3’ untranslated region (UTR) and promoting 
BRCA1 mRNA degradation [116]. 
2.4.4 Regulation by estrogen (E2) 
Many studies have shown that the hormone E2 regulates BRCA1, however the exact 
mechanism of E2-stimulated transcriptional activation is still unclear. In the classical 
model, E2 binds to an E2 response element (ERE) located at a gene promoter to activate 
transcription [117]. However, the BRCA1 promoter does not contain a canonical ERE [104, 
118]. Furthermore, the ER antagonist, tamoxifen, does not repress ability of E2 to induce 
BRCA1 [119]. It is therefore generally accepted that E2 stimulates BRCA1 transcription 
indirectly, for example by stimulating association of ER and/or activators to alternate EREs 
such as AP1 or Sp1 binding sites [104]. During E2 stimulation, ER associates with AP1 
members, c-Jun and FosB and the histone acetyltransferase, p300 [104]. This complex is 
then recruited to the AP1 site to activate BRCA1 transcription [104]. More recent studies 
have shown that MyoD and c-myb forms activating transcriptional complexes with 
transcriptional factors p300 and PCAF, which increases histone acetylation and 
transcriptional activation of BRCA1, upon E2 stimulation [120]. Another recent study also 
showed BRCA1 was relieved of CtBP1 repression upon E2 stimulation [121]. Hence E2 
most likely promotes BRCA1 transcription through multiple TFs binding sites on the 
BRCA1 promoter. BRCA1 is also regulated by the estrogen receptor, which will be further 
elaborated under long-range transcriptional regulation in section 2.5.8. 
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2.5 Long-range Transcriptional Regulation 
2.5.1  Cis- and trans- regulatory elements 
Transcriptional control of gene expression is dependent on a tightly regulated interplay of 
protein-DNA and protein-protein interactions [122]. RNA polymerase II (Pol II) is an 
essential component of the basal transcription machinery, which binds to the promoter to 
drive transcription (reviewed in [123]). TFs and accessory molecules modulate Pol II 
function by mediating interactions between the promoter and proximal or distal regulatory 
elements. Proximal elements are located within a few hundred base pairs of a TSS, and 
distal elements are usually located more than 1kb from a TSS or indeed can be on a 
different chromosome [124]. Cis-regulatory elements are located on the same 
chromosome as the gene they regulate. In contrast, trans-regulatory elements are located 
on a different chromosome. There are currently four different classes of distal regulatory 
elements, namely enhancers, silencers, insulators and locus control regions [125]. 
2.5.2  Enhancers 
Enhancers are short DNA sequences that can activate gene expression. Enhancers can 
act in an orientation-dependent or -independent manner [126-128], and can be located 
upstream, within or downstream of their target gene[129]. Pol II appears to be important 
for enhancer activity, whether it is preloaded at a promoter or is subsequently recruited to 
a promoter or enhancer [130, 131]. When Pol II and TFs are pre-loaded on a promoter, 
activators and co-activators bind to enhancer elements, which in turn interact with the 
promoter and initiate transcription. For example, Pol II is pre-loaded on the major 
histocompatibility class II (MHCII) promoters in Hela cells, however, this complex is 
normally inactive [130]. Upon stimulation by gamma interferon (IFN-γ), three activators, 
CREB, NFY and RFX bind to enhancer elements located near MHCII promoters, recruiting 
the co-activator CIITA which is required for chromatin remodelling and transcriptional 
activation [130]. Pol II and TFs can also be first recruited to an enhancer before binding to 
the promoter as in the case of transcribed enhancers [132, 133]. In this case, transfer of 
Pol II and TFs, together with activators/co-activators from enhancers to the promoter is 
essential for driving transcription.  
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2.5.3 Silencers 
Silencers are DNA elements that inhibit or repress transcription and can be classified into 
two broad types; silencer elements (SE) and negative regulatory elements (NRE). SEs are 
usually position-independent and inhibit transcription by interfering with TF assembly. For 
example, an SE located 1kb from the TSS of bradykinin B2 receptor (BKB2R), showed 
position-independent silencing in reporter assays [55, 134]. In contrast, NREs are usually 
position-dependent and direct passive repression by preventing TF binding to cis-
regulatory elements [135]. For example, the 5’ UTR of human α1-chimerin (CHN1) showed 
position-dependent silencing, suggesting an NRE is located within this region [136]. 
Silencers can also be further classified as orientation-dependent or according to silencer 
position as in the case of intron-located silencers. There also exist some rare occasions 
where silencers are classified as promoter-dependent, for example the human growth 
hormone 1 (Hgh1) silencer located approximately 2kb downstream of Hgh1 [137].  
2.5.4 Insulators 
Insulators are DNA elements that function as barriers to separate heterochromatin from 
euchromatin [138]. For example, the DNase hypersensitive 5'HS4 insulator of β-globin is a 
major site of histone acetylation. Evidence suggests that this insulator works by 
maintaining constitutive histone H3K9 acetylation in the adjacent nucleosome, which 
prevents H3K9 methylation and chromatin condensation [138]. Another function of 
insulators is to physically block the enhancer/silencer:promoter interaction by being 
located between these two elements [139]. One example would be the M(340) insulator, 
which blocks the enhancer of white genes from the repressive polycomb response 
element, thus influencing eye colour in Drosophila [140, 141]. Currently, there is only one 
know mammalian insulator protein called CCCTC-binding factor (CTCF) [142]. Several 
studies have demonstrated that binding of CTCF to specific DNA elements can facilitate 
enhancer blocking and/or act as a barrier to the spread of heterochromatin [143-145]. 
2.5.5 Locus Control Regions (LCRs) 
LCRs consist of multiple DNA regulatory elements which usually fall within DNase I 
hypersensitivity (HS) regions and are able to enhance or repress expression of transgenes 
in a copy number-dependant and position-independent manner [146]. The most well 
characterised LCR is that regulating the human -globin locus [147-149]. This LCR 
consists of five HS sites that are located 6-20kb upstream of the five β-type globin genes 
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on chromosome 11 [150]. Many studies have demonstrated that this LCR is essential for 
driving high-level and correct developmentally timed expression of the globin genes [151-
153]. Interesting, LCR scan also be located in a completely different gene. For example, 
exons 19 to 23 of Fmn (Formin) contains the LCR of a downstream gene called GREM1 
(gremlin 1), which encodes for a bone morphogenic protein. Down regulation of GREM1 
causes severe form of limb deformity hence it is more accurate to associate GREM1 rather 
than Fmn to this disorder [154]. While most LCRs are associated with enhancer activity, 
LCRs can also be repressive. When γ-globin and β-globin were cloned together with their 
LCR, the LCR element HS3 promoted β-globin while repressing γ-globin [147]. This data 
supports the notion that an LCR can act as an enhancer for one gene but act as a 
repressor on another.  
2.5.6  Chromatin Looping 
As previously mentioned, most distal-acting regulatory elements are located more than 
1kb from their target genes. Therefore, control of transcription often involves long-range 
DNA associations, which can be mediated by chromatin loops (Figure 6) [155]. In this 
looping model, distal regulatory elements contact the promoter through their associated 
proteins, with the intervening DNA being looped out. Intra-chromosomal (cis-) looping 
occurs on the same chromosome as the target gene whereas inter-chromomosomal 
(trans-) looping occurs between different chromosomes (Figure 6). Looping patterns often 
change upon gene activation, suggesting that looping is involved in transcription and 
therefore tightly regulated [2]. However, the presence of a chromosomal loop does not 
always indicate transcriptional regulation. For instance, detection of intra-chromosomal 
loops within the 200kb Th2 locus did not vary significantly between resting and activated 
Th2 cells [156]. This suggests that some loops might be constitutively present at this locus. 
In contrast, the inter-chromosomal looping between Th2 on chromosome 11 and the 
promoter region of IFN-γ on chromosome 10 appears to be functional as this interaction is 
lost upon gene activation during differentiation of naïve T cells to effector T cells [124]. 
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Figure 6. Looping model of long-range transcriptional control. An enhancer or 
silencer element (red circle) can interact with the promoter (grey box) of a gene through 
DNA looping. Intrachromosomal looping is demonstrated in gene one (blue rectangle) and 
interchromosomal looping is demonstrated in gene two (green rectangle) [157]. 
2.5.7 Trans-acting factors  
In addition to DNA elements, trans-acting factors are also important for mediating 
chromosomal looping. Trans-acting factors can be proteins or non-coding RNAs that 
regulate gene expression. The formation of chromatin loops requires the action of many 
trans-acting factors such as TFs, co-activators, structural maintenance of complexes, 
insulator proteins, polycomb repressor complexes and non-coding RNA (Table 1). 
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Protein Name Classification Implicated in 
Breast Cancer? 
Reference/s 
AP1 TF Yes* [158, 159] 
AP-2γ TF Yes* [160, 161] 
EKLF TF ND [162] 
ER TF Yes* [163, 164] 
FOG-1 TF ND [165] 
FoxA1 TF Yes* [166] 
GATA-1 TF ND [165] 
GATA-2 TF ND [149] 
GATA-3 TF Yes* [159, 167] 
NL1/Ldb1 TF ND [168] 
PR TF Yes [169] 
STAT6 TF ND [167] 
Brg1 Chr remodelling ND [170] 
Ezh2 Polycomb Yes [171, 172] 
Pc Polycomb ND [173] 
CTCF Insulator Yes [88, 174] 
Cohesin Architectural Yes* [175] 
PML Architectural ND [176] 
SATB1 Architectural Yes [177, 178] 
Mediator Coactivator ND [179, 180] 
p300/CBP Coactivator Yes* [181, 182] 
SRC1-3 Coactivator Yes* [183] 
 
Table 1. List of proteins associated with establishing or maintaining chromosomal 
looping and their involvement in breast cancer. *proteins implicated in ER-mediated 
chromatin loops. ND represents unknown or not determined. Adapted from [184]. 
2.5.8  Estrogen Receptor (ER) 
One of the key TFs involved in both breast cancer and chromatin looping is the ER [185-
187]. There are two types of classical ERs, namely ERα and ERβ [188]. Since both forms 
are expressed in cells, the ER can form ERαα or ERββ homodimers or ERαβ 
heterodimers, even in the absence of the E2 ligand [189, 190]. When IGF-IR (Insulin-like 
growth factor 1) is silenced in MCF7 cells, ERα expression decreases whereas ERβ 
expression increases and this change in ERα/ERβ ratio has been suggested to contribute 
to breast cancer progression [191]. Both ERα and ERβ are detected at the plasma 
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membrane, however, detection of ERβ is much lower than ERα [192]. This suggests that 
ERα is the predominant form involved in signalling-dependent gene regulation by E2. 
Microarray and ChIP-Seq analysis of ER-positive breast cancer cell lines have identified 
hundreds of ER-regulated genes however the majority of these genes have not been 
clearly associated with breast cancer [163, 164]. 
The classical model of ER-mediated gene regulation involves the binding of E2 with ER 
in the nucleus, this E2-ER complex then binds to EREs in the promoters of target genes, 
to elicit a transcriptional response [193] (Figure 7). ER can also regulate genes in a ligand-
independent manner. In this model, plasma membrane bound ER is activated by E2, 
leading to activation of intracellular kinase pathways that result in phosphorylation of TFs 
at a different response element at the promoter. Furthermore, a membrane-bound non-
classical ER, G protein-coupled receptor (GPR30), has also been shown to participate in 
this ligand-independent signalling dependent model [194-196]. In the ERE-independent 
model, E2 binds to ER in the nucleus and the E2-ER complexes regulate gene 
transcription through alternative response elements such as AP1 and other DNA-bound 
transcription factors such as Fos and Jun that anchors E2-ER to the DNA [197]. 
Interestingly, binding of E2 to ER increased the half-life of ER-dimers by three fold in vitro 
and is thought to be important in determining the half-life of the ERE-bound ER dimer 
during gene regulation in vivo [198]. When different ligands bind to the ERligand-binding 
domain, the half-life changes which affects the in vivo potency and efficacy of a particular 
ligand at different gene promoters [198]. 
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Figure 7. Mechanisms of E2 and ERsignaling. Transcriptional regulation by E2 is 
mediated through three ER pathways. (1) The classical ligand-dependent model; (2) the 
ligand-independent model; and (3) the ERE-independent model. Adapted from [197]. 
  
  33 
2.5.9 Other proteins implicated in chromatin looping 
As mentioned previously, the AP1 family of TFs are involved in long-range regulation of c-
Myc by interacting with ER at the AP1 site [182]. The AP-2 (activating protein 2) TF family 
such as AP-2α and AP-2γ, have also been reported to mediate transcription of ER-induced 
genes such as CARBPII (cellular retinoic acid-binding 2) [199]. In addition, AP-2 has been 
implicated in looping between distal enhancer elements located 1.7kb downstream of 
KER1 (keratin 1) [199, 200]. Besides AP-2, several papers have shown that FoxA1 
(Forkhead box protein A1) is involved in ER-dependent long-range regulation [166]. ChIP 
analysis using FoxA1 antibodies revealed FoxA1 overlapped with 48% of ER-associated 
regions found on chromosome 21 and 22 [166]. Moreover, ER ChIP and qRT-PCR 
showed that knockdown of FoxA1 abolished ER binding to the XBP-1 (X-box binding 
protein 1) and NRIP-1 (Nuclear receptor-interacting protein 1) enhancers and the TFF1 
(Trefoil factor 1) promoter, which inhibited E2 activation of these genes [166]. In addition, 
electrophoretic mobility shift assays demonstrated that ER binds to an enhancer located 
approximately 10kb upstream of TFF1, which resulted in recruitment of co-activators such 
as SRC1 (steroid receptor coactivator-1), CBP and CARM1 (coactivator-associated 
arginine methyltransferase 1) at both the TFF1 enhancer and promoter [185]. Taken 
together, these results show that FoxA1 is intimately linked to ER-mediated long-range 
regulation and FoxA1 might facilitate recruitment of co-activators. ER is also bound to the 
GATA3 (GATA-binding protein 3) enhancer located approximately 9.8kb downstream of 
GATA3, and this binding can activate GATA3 transcription. GATA3 in turn binds to two 
distal enhancers of ER located more than 100kb upstream of ER, resulting in a positive 
feedback loop in T47D and MCF7 breast cancer cells [201, 202]. Hence, GATA3 is also 
involved in ER transcriptional activation as well as ER-mediated long-range regulation.  
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2.6 Long-range regulation and breast cancer 
Currently, only a few studies have identified long-range cis-regulatory elements associated 
with breast cancer. Importantly, a significant number of these interactions are dependent 
on ER. CA12 (Carbonic anhydrase XII) is transcriptionally activated via ER-mediated 
looping by a distal enhancer located ~6kb upstream of its TSS [203]. CA12 is a prognostic 
marker for invasive cancer and is expressed in 75% of invasive breast cancers [204]. 
CTSD (Cathepsin D) is also induced by an E2-responsive enhancer located 9kb upstream 
[205]. CTSD is overexpressed in a subset of breast tumours and is associated with 
metastasis and poor prognosis [206]. Another study has also demonstrated that RET 
(receptor tyrosine kinase) expression is up regulated in a subset of ER-positive invasive 
breast tumours [207]. Following E2 stimulation, ER-mediated looping occurs between the 
promoter and two enhancers located 49.8kb upstream and 32.8kb downstream of RET, 
which activates transcription in MCF7 breast cancer cells [208, 209].  
Finally, the proto-oncogene c-Myc can be induced by E2 [210, 211]. c-Myc is a prognostic 
marker which can predict recurrence in node-negative breast cancer patients [212]. c-Myc 
transcription is activated through chromatin looping of a distal enhancer located 67kb 
upstream of the TSS with the c-Myc promoter. This interaction is mediated by both ER and 
AP1 upon E2 induction [182]. Interestingly, c-Myc is also controlled by multiple distal 
enhancer elements in a breast cancer risk region located more than 300kb centromeric 
from c-Myc in MCF7 cells, however the TF involved in this interaction is still unknown 
[213]. A separate study found that the Tcf-4 TF mediated looping of enhancers within 
colon/prostate risk regions at this locus [214]. It will be interesting to investigate if Tcf-4 
also mediates looping of enhancers from the breast cancer risk region.  
There are also several ER-independent long-range interactions implicated in breast 
cancer. For example, BCL2 (B-cell lymphoma 2) encoding the proto-oncogene and 
prognostic marker, contains an enhancer element in its 3’UTR, 200kb downstream of the 
promoter [215]. This BCL2 intra-chromosomal enhancer-promoter looping is mediated by 
SATB1 [216]. In addition, CDKN1A encodes p21 whose loss is associated with therapeutic 
resistance and poorer 5-yr survival rate as compared to p21 positive breast cancers [217, 
218]. Vitamin D stimulated looping between the promoter and three vitamin D response 
elements located 7kb upstream of the promoter, leading to increased CDKN1A expression 
[219, 220]. These examples of long-range interactions implicated in breast cancer have 
been elucidated by performing 3C. Aside from long-range regulation of various genes 
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associated with breast cancer, there also have been a couple of studies implicating long-
range regulation of BRCA1.  
2.6.1 Long-range regulation of BRCA1 
Currently, there are only two papers describing long-range control of BRCA1, both of 
which have been published by senior researchers of my current group. Using bio-
informatically identified evolutionary conserved regions and reporter assays, Wardrop et al 
identified a putative enhancer and silencer element within BRCA1 intron 2, approximately 
5kb downstream of the BRCA1 promoter [1]. However, due to the limitations in technology 
at the time, direct evidence for an interaction between these elements and the BRCA1 
promoter was not shown. In a more recent study, Tan-Wong et al used chromatin 
conformation analysis to show an interaction between the BRCA1 promoter and terminator 
region, located more than 80kb downstream of the BRCA1 TSS [2]. Loss of this interaction 
was observed on E2-induced activation of BRCA1 transcription in MCF7 cells [2]. 
Consistent with this, an increased interaction was also shown between the promoter and 
terminator regions in lactating mice when BRCA1 is repressed as compared to pregnant 
mice whereby BRCA1 is up regulated. The presence of transcriptional silencer elements in 
the BRCA1 terminator region suggests that these interactions may participate in BRCA1 
repression; however this is yet to be directly proven.  
2.7 Methods for detecting Long-range control elements 
Despite the clear importance of distal regulatory elements in breast cancer, difficulties 
encountered in the detection and analysis has so far limited the research in this field. 
Efficient investigation of long-range DNA interactions has only recently become feasible 
with the development of bioinformatic tools and chromosome conformation capture (3C) 
based techniques [157].  
2.7.1 Bioinformatics Analysis  
It is now well accepted that distinct histone modifications are associated with specific 
regions of the genome, such as promoter regions, enhancer regions and transcribed 
regions, depending on the type of modification and position of modified amino acid 
(reviewed in [221]). For example, tri-methylated histone H3K36me3 marks regions of 
RNAPol II elongation, whereas dimethylated H3K9 is indicative of DNA methylation and 
therefore associated with gene silencing [222, 223]. Therefore, histone marks are useful 
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epigenetic markers for inferring if a gene might be active. For this project, the focus will be 
on trimethylation of histone 3 lysine 4 (H3K4Me3) which is associated with active 
promoters, and mono- and dimethylation of histone 3 lysine 4 (H3K4Me1 and H3K4Me2) 
which is associated with active promoters and enhancers [224]. 
2.7.2 Chromosome Conformation Capture (3C) 
3C is a powerful approach for identifying interactions between distant DNA regions. This 
technique consists of four main steps (Figure 8). The first step involves chemical fixation of 
cells with formaldehyde to cross-link proteins such as TFs and histones to DNA. The 
second step involves digestion with a restriction enzyme to separate non cross-linked DNA 
from cross-linked DNA. The third step involves ligation of cross-linked DNA. Finally, the 
forth step involves de-crosslinking proteins from DNA, followed by DNA purification. PCR 
primers specific to the region of interest, coupled with a bait primer, can then be used to 
analyse a 3C library using quantitative real-time PCR [157, 225]. When performing 3C, it is 
important to keep in mind that due to the intrinsic flexible property of the chromatin fiber, 
DNA regions on the same chromosome tend to engage in random collisions; the shorter 
the genomic distance, the more frequent random collisions occur [225]. Therefore, simply 
detecting a ligated product does not always imply a specific interaction. To confirm that an 
interaction is functionally relevant requires that two DNA regions interact more frequently 
with each other than neighbouring regions. Another limitation is that 3C is a candidate 
approach to finding interacting regions therefore prior knowledge of the potential 
interacting region is required for primer design [226]. 
3C has been used to study the regulation of genes in multiple eukaryotic species with data 
supporting the looping model for gene activation and repression. For example, 3C was 
used to show that the promoter region of IFN-γ on chromosome 10 interacted with 
conserved regions in the cytokine locus on chromosome 11 in mouse [124]. These 
interactions were proposed to be repressive as they were lost upon IFN-γ transcriptional 
activation during differentiation of naïve T-cells to T-helper cells [124]. As mentioned 
previously, interacting regions does not necessarily prove that those regions are 
functional; therefore 3C studies are usually followed by functional assays. For example, 
Gheldof et al used 3C and luciferase reporter assays to demonstrate that the cystic fibrosis 
transmembrane conductance regulator (CFTR) promoter interacts with enhancer elements 
located more than 100kb downstream [227]. In addition, COX (cytochrome c oxidase) is a 
bigenomic protein consisting of ten nucleus-encoded subunits and three mitochondrial-
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encoded subunits [228]. Interestingly, 3C has revealed that all 13 genes interact with each 
other, regardless of whether the genes are located in the nucleus or mitochondria in 
murine neurons [228]. The authors have proposed that these inter-chromosomal loopings 
gather the genes together in the nucleus, enabling them to be transcribed simultaneously 
using the same transcription machinery in mammalian neurons. Therefore chromosomal 
looping might facilitate co-ordinated gene transcription of multiple subunits of a large 
protein in addition to being involved in gene regulation.  
 
 
 
Figure 8. Chromosome conformation capture (3C) and circular-3C (4C) analysis of 
long-range interactions. 3C involves crosslinking DNA to proteins, digestion with a 
restriction enzyme, ligation of DNA fragments and reverse crosslinking. 3C DNA is then 
purified and amplified via PCR for analysis. 4C involves 2 additional steps. After reverse 
crosslinking in 3C, DNA is digested with another restriction enzyme and then ligated. 4C 
DNA is then purified and amplified via inverse PCR. Modified from Dr Stacey Edwards. 
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2.7.3 Circular-3C (4C) 
4C is a modified version of 3C with two additional steps inserted (Figure 8) [225]. Firstly, 
DNA is digested with a second restriction enzyme, which cuts at more frequent intervals. 
This trims the ligated product to a smaller, more manageable size. Secondly, the digested 
DNA fragments undergo another ligation. The resulting DNA fragments are then purified 
and amplified by inverse PCR using bait specific primers. 4C analysis is then performed by 
either next generation sequencing or microarrays. An advantage of 4C is that it is a 
genome-wide unbiased approach, which reveals interacting DNA regions from both intra- 
and inter-chromosomal looping. For example using the CTCF binding site as bait, 4C has 
revealed Arhgap6 (Rho GTPase activating protein 6) located on the chromosome X, 
interacts with Bcl11b (B-cell lymphoma/leukemia 11B) on chromosome 14 in MCF7 cells 
[229]. In addition, 4C can be used in combination with other methods. For example, Choi 
et al employed a novel 4C-ChIP-cloning technique to identify four long-range interactions 
mediated by RNF2, a core component of polycomb repressive complex 1 [230]. RNF2 
knockdown resulted in increased gene expression of NF2 (Neurofibromin 2), CAST 
(calpastatin), ZNF248 (zinc finger protein 248) and an un-named gene, BC029570.1 
thereby further supporting the hypothesis that these interactions are repressive [230].  
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3  RESEARCH HYPOTHESIS AND AIMS 
3.1 HYPOTHESIS 
The hypothesis underlying the proposed research is that there exist yet unidentified novel 
long range regulatory elements of BRCA1 that are important for the appropriate regulation 
of BRCA1 expression.  
3.2 PROJECT AIMS 
3.2.1 AIM 1:  
Identify novel long-range DNA sequence elements that associate with the BRCA1 
promoter using a candidate chromosome conformation capture (3C) approach. 
3.2.2 AIM 2:  
Identify novel long-range DNA sequence elements that associate with the BRCA1 
promoter using an unbiased genome-wide circular-3C (4C) approach. 
3.2.3 AIM 3:  
Determine whether sequences identified in Aims 1 and 2 can enhance or repress 
transcriptional activity of the BRCA1 promoter. 
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4 MATERIALS AND METHODS 
4.1  Bioinformatics 
The UCSC genome browser (http://genome.ucsu.edu/) was used to identify putative 
regulatory elements within the BRCA1 genomic region. This analysis integrated multiple 
genome-wide data sets, including ChIP-seq for histone modifications such as H3K4Me1, 
H3K4Me3 in HMECs (ENCODE data) and for TF binding and DNase hypersensitivity. The 
UCSC mammalian conservation tracks included placental mammal conservation, which 
compared rhesus monkey, mouse lemur, mouse, cat, dog, elephant and vertebrate 
conservation which compared across platypus, chicken and fugu. The UCSC human 
genome used for all analysis and genomic co-ordinates is GRCh37/hg18. In addition, the 
JASPAR online database (http://jaspar.genereg.net/cgi-bin/jaspar_db.pl) was used to 
identify binding motif for c-Myc in Homo Sapiens.  
4.2 Cell culture 
MCF7 cells were a kind gift from Dr Alison Butt, Garvan Institute, Sydney. A2780 and 
OVCAR3 were a kind gift from Prof Georgia Chenevix-Trench, the Queensland Institute for 
Medical Research, Brisbane. T47D cells and MDA-MB-231 cells were purchased from 
ATCC. MCF7 and T47D cells were cultured in RPMI 1640 media (Gibco Invitrogen, CA, 
USA) containing 10% fetal bovine serum (FBS; Gibco Invitrogen, CA, USA), 10ug/ml anti-
biotic/anti-mycotic cocktail (Gibco Invitrogen CA, USA), 1mM sodium pyruvate (TRACE 
Scientific Ltd, Melbourne, Australia), 20mM HEPES (TRACE Scientific Ltd, Melbourne, 
Australia) and supplemented with 10ug/ml insulin from bovine pancreas (Sigma Aldrich). 
MDA-MB-231, A2780 and OVCAR3 were cultured in RPMI 1640 media containing 10% 
FBS and 10ug/ml antibiotic/antimycotic cocktail. All cells were maintained at 37ºC, 5% CO2 
in a humidified incubator. 
4.3 RNA extraction and cDNA synthesis  
RNA was extracted from MCF7 or T47D cells, with or without E2 treatment using Trizol 
(Invitrogen) according to manufacturer’s protocol. Reverse transcription was performed 
using SuperScript III First-Strand Synthesis Kit (Invitrogen) with 500ng of RNA and 50ng 
random hexamers according to the manufacturer’s protocol. 
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4.4 Quantitative Real Time PCR (qRT-PCR) 
cDNA was analysed via qRT-PCR using Taqman universal master mix (Applied 
Biosystems) and Taqman probes (Applied Biosystems) BRCA1 Hs01556193_m1, TFF1Hs 
00907239, c-Myc Hs00905030_m1 and housekeeping β-Glucuronidase, GUSb 
Hs99999908_m1 on a Corbett Rotor-gene 6000 as per manufacturers’ instructions. 
4.5 Chromosome Conformation Capture (3C)  
Cells were harvested for 3C at 60%-70% confluent 10cm dish. Cells were washed once 
with 1x PBS and fixed with 1% Paraformaldehyde (Invitrogen) dissolved in PBS (Sigma 
Aldrich, USA), for 10min. One wash with 0.125M Glycine in PBS was used to quench 
remaining paraformaldehyde. Cells were scraped on ice in cold 0.125M Glycine/PBS and 
washed once with cold PBS. Cell pellets were resuspended in lysis buffer and incubated 
on ice for 30min before applying to the homogeniser. Lysis buffer consisted of 10Mm Tris 
pH 7.5, 10mM NaCl, 0.2% IGEPAL (Sigma Aldrich, USA), 1 complete protease inhibitor 
tablet (Roche, USA) in Dnase/Rnase free water (Gibco Invitrogen USA). Nuclei pellets 
were collected from centrifugation. Nuclei pellets were resuspended in 1x enzyme buffer 
(New England Biolabs) with 0.3% SDS and incubated at 37ºC for 1 hr. Triton-X (Final 
concentration 2%) was added to samples and incubated at 37ºC for 1 hr. 1500U of 
restriction enzyme was added to each sample and incubated overnight at 37ºC. SDS 
(Final conc. 1.6%) was added to samples and heated at 65ºC for 30min. Samples were 
ligated with 4000U T4 ligase, final ligation volume was 8ml. DNA was purified using the 
phenol-chloroform method. 
Two BAC clones (RP11-769M9 and RP11-266I24) covering the BRCA1/AARSD1 region 
were used to create an artificial library of ligation products in order to normalize for PCR 
efficiency (Appendix table 1 and 2 shows primer list used in PCR). Data were normalized 
to the signal from the BAC clone library and, between cell lines, by reference to a region 
within the GAPDH gene. All Q-PCR products were electrophoresed on 2% agarose gels, 
gel purified and sequenced to verify the 3C product. A well-characterised interaction 
between the BRCA1 promoter and terminator region of BRCA1 was also used as an 
internal control to check 3C library integrity [2]. 
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4.6 Estrogen induction for 3C  
17 beta-estradiol (E2) (Sigma Aldrich) was dissolved in Dimethyl sulfoxide (DMSO) (Ajax 
Finechem Pty Ltd, NSW, Australia). MCF7 or T47D cells were seeded onto 100mm dishes 
and treated for 48h with 10nM Fulvestrant, also known as Faslodex (ICI 182780, Sigma 
Aldrich) followed by 0-48h of 100nM E2 without media change [231]. Vehicle samples 
were also treated with Fulvestrant but contained DMSO instead of E2. 
4.7 Construction of luciferase reporter vectors  
The BRCA1 promoter-driven luciferase construct was generated by inserting a 500bp 
fragment containing the BRCA1 promoter 1α into the XhoI site of pGL3-Basic (Promega) 
[1]. PRE1 was PCR amplified from BAC RP11-266I24 and cloned into the BamHI/SalI site 
pGL3-BRCA1 promoter or pGL3 promoter (Promega). Sequences were verified by the 
Australian Genome Research Facility (AGRF; University of Queensland, Brisbane, 
Australia). 
4.8 Transient transfection and luciferase assays 
MCF7 cells were transiently transfected with 600ng of each pGL3 construct and 50ng of 
pRL-TK (Promega) using 1ul of Lipofectamine 2000 (Invitrogen) per well in a 24-well plate. 
Luciferase activity was measured 24h post-transfection using a dual luciferase reporter 
assay (Promega) and the Beckman Coulter DTX 880 multimode detector according to the 
manufacturers’ protocol. To compensate for any variation in transfection efficiency, firefly 
luciferase were normalised to that of Renilla. Data shown are the mean ± SD from three 
technical replicates.  
4.9 Estrogen induction for luciferase assays 
MCF7 cells grown in 10% charcoal-stripped FBS (Gibco Invitrogen) were seeded 7.5x104 
cells per well in 24 well plate 24h prior to transfection. Cells were washed once with PBS 
and media was changed to exclude anti-biotic/anti-mycotic just before adding the 
transfection mixture. Transfection procedure was executed as described above. An E2-
inducible luciferase construct containing three EREs (Addgene plasmid 11354) was used 
as a positive control for E2 induction [117]. Luciferase activities were measured 48h post-
transfection. 
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4.10 Small interfering RNA (siRNA) 
SMARTpool siRNAs for c-Myc and control were purchased from (Dharmacon). MCF7 cells 
were seeded at 1.5x105 cells/well in a 12 well plate 24h prior to transfection. MCF7 cells 
were then co-transfected with 50ng of pRL-TK (Promega), 600ng of pGL3 (Promega) 
constructs and 100nM of siRNA using 1ul of Lipofectamine 2000 in opti-MEM (Invitrogen). 
Luciferase activities were measured 72h post-transfection. 
4.11 Western Blotting 
Cells from a 10cm plate were harvested at 80% confluency using 200µl RIPA buffer (50 
mMTris-HCL (pH 7.5), 150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 
1mM Na3VO4, 1mM PMSF, 1x protease inhibitor). The lysates were incubated on ice for 
30 minutes and centrifuged for 20 mins at 13,000 rpm at 4C to remove insoluble cell 
debris. BCA protein assay kit #23227 (Pierce) was used to quantify amount of protein 
present. The lysate was run in the X Cell Surelock tank (Invitrogen) using NuPAGEMOPS 
SDS running buffer and 4-12% Bis-Tris precast gel (Invitrogen) at 200V. Proteins were 
transferred to 0.45um polyvinlidene fluoride transfer membrane (PVDF) (BioTrace) and 
probed with anti-c-Myc antibody (sc-764X, Santa Cruz Biotechnology, Inc.) or anti actin 
antibody (A2066, Sigma Aldrich) overnight in 5% milk dissolved in TBS-Tween. The anti-c-
Myc and anti-actin primary antibodies were diluted 1:10,000 and 1:3,000 respectively. 
Signals were detected using ECL prime Western blot detection reagent (GE healthcare) 
and medical XRAY film SUPER RX Cat # 4741008389 (FUJI FILM) in X-Ray Film 
automatic processor XP-9000 (DLC). 
4.12 ChIP (Chromatin Immunoprecipitation) 
Chromatin immunoprecipitation assays were performed using the ChIP-IT® Express 
Enzymatic kit (cat # 53009) according to the manufacturer’s protocol (Active Motif) using 
1.5 × 107 MCF7 cells and 10min of optimised enzymatic shearing time. 5ug of anti-c-Myc 
antibody (sc-764X, Santa Cruz Biotechnology, Inc.) or anti-IgG (sc-2027, Santa Cruz 
Biotechnology, Inc) was used to precipitate cross-linked DNA-protein complexes, and the 
normal isotype-matched IgG from the same species was used as negative control. Refer 
to Appendix table 3 for ChIP primer sequences. 
  44 
5 Results – CHAPTER 1 
5.1 Identification of long-range regulatory elements located 157kb downstream of 
the BRCA1 promoter 
 
In 2008, Tan-Wong et al described the use of 3C to identify DNA elements within the 
BRCA1 locus that physically interact with the BRCA1 promoter [2]. The first aim of this 
project was to extend this analysis to identify potential long-range regulatory elements 
upstream of the BRCA1 promoter or downstream of the BRCA1 terminator. We initially 
performed 3C using MCF7 cells as they express moderate levels of BRCA1. We used a 
PCR bait primer located in the HindIII fragment that contains the BRCA1 promoter in 
combination with primers designed to HindIII fragments mapping up to 200kb downstream 
and 70 kb upstream of the BRCA1 promoter (Figure 9A). The results suggested the 
BRCA1 promoter fragment frequently interacted with two HindIII fragments downstream, 
located 143kb and 157kb away from the BRCA1 TSS, respectively (Figure 9B). As the 
157kb fragment was the more consistent of the two interacting regions (a second 
biological replicate is shown in Appendix Figure 1) and demonstrated the highest 
interaction frequency, this fragment was prioritized for further study. This HindIII fragment 
will now be called Putative Regulatory Element1 (PRE1) and is approximately 12kb in size 
(Figure 9B, Appendix Figure 1, highlighted in grey) and spans introns 6 to 9 of a nearby 
gene called alanyl-tRNAsynthetase domain containing 1 (AARSD1). In contrast to 
downstream of BRCA1, there were no significant interactions between the BRCA1 
promoter and HindIII fragments upstream in MCF7 cells (Figure 9C). 
 
To confirm this novel interaction between the BRCA1 promoter and PRE1, a second 3C 
library was generated using NcoI in MCF7 cells. 3C was performed using a PCR bait 
primer located in the NcoI fragment that contains the BRCA1 promoter in combination with 
primers designed to NcoI fragments mapping to regions between RUNDC1 exon 1 to 
AARSD1 exon 12, located 144kb to 174kb downstream of the BRCA1 promoter 
respectively (Figure 10A). Consistent with our previous results, the NcoI fragment 
corresponding to PRE1 interacts frequently with the BRCA1 promoter (Fig. 10B). The 
region overlapping PRE1 and corresponding NcoI fragements region is now 10,875bp in 
size. 
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Figure 9. 3C reveals two elements that interact with the BRCA1 promoter in MCF7 
cells. (A) Schematic diagram of the BRCA1 genomic region and HindIII fragments used 
for 3C analysis. P represents the BRCA1/NBR2 bi-directional promoter. Black vertical lines 
at the bottom indicate HindIII sites, black arrows indicate direction of transcription and 
black blocks indicate exons. The break (//) starts after BRCA1 exon 2 and ends before 
AARSD1 exon 1. The grey box represents PRE1 (diagram not drawn to scale). 3C 
interaction profiles of BRCA1 downstream (B) and upstream (C) HindIII fragments in 
MCF7 cells. Results were derived from three pooled biological 3C libraries. Data shown 
are the mean ± SD from two technical replicates. Refer to Appendix Table 1 for primer 
sequences.  
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Figure 10. 3C confirms that PRE1 interact with the BRCA1 promoter in MCF7 cells. 
(A) Schematic diagram of the BRCA1 genomic region and NcoI fragments used for 3C 
analysis. P represents the BRCA1/NBR2 bi-directional promoter. Black vertical lines at the 
bottom indicate NcoI sites, black arrows indicate direction of transcription and black blocks 
indicate exons. The break starts after BRCA1 exon 1b and ends before RUNDC1 exon 1. 
The grey highlighted region represents the NcoI fragment that overlaps with PRE1 
(diagram not drawn to scale). (B) 3C interaction profile of NcoI fragments in MCF7 cells. 
Results were derived from three pooled biological 3C libraries. Error bars represent SD of 
two technical replicates. Refer to Appendix Table 2 for primer sequences. 
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5.2 The frequency of long-range interactions between the BRCA1 promoter and 
PRE1 correlates with BRCA1 transcription upon E2 treatment in MCF7 cells. 
BRCA1 transcription is induced upon treatment with E2, however the mechanism of this 
induction is not fully understood. We sought to determine whether the frequency of the 
chromatin interaction between the BRCA1 promoter and PRE1 changed when MCF7 cells 
are stimulated with E2. To address this question, we first performed a time-course 
experiment in MCF7 cells to determine the optimal time post-E2 induction to harvest cells 
for 3C. Initially we had very little BRCA1 induction by E2, approximately two fold 
regardless of cell line and estrogen concentration. This was a problem because if BRCA1 
was not significantly induced, chromosome conformation techniques might not be able to 
detect the changes in interaction frequency between the BRCA1 promoter and potential 
novel regulatory elements. To obtain a higher BRCA1 induction, Fulvestrant was used to 
treat cells prior to E2 treatment. Our data suggests that Fulvestrant together with estrogen 
induces higher BRCA1 expression as compared to estrogen alone, over 10 fold as 
compred to the initial 2 fold (Figure 11A). Interestingly, Fulvestrant has already been 
shown to be able to transform an E2-induced apoptotic signal to an E2-induced growth 
signal in MCF7 cells [232]. Vehicle samples were also initially treated with Fulvestrant and 
subsequently treated with DMSO instead of E2. As we obtained our MCF7 line from Dr 
Alison Butt, we used their published fulvestrant/E2 protocol to induce BRCA1 [233]. RNA 
was harvested from fulvestrant (ICI 182,780) treated cells seeded in 12-well plates 
between 0-48h following E2-treatment. The preliminary results suggested that the 36h post 
fulvestrant/E2 treatment increased BRCA1 mRNA levels, with a 12-fold increase in BRCA1 
mRNA levels as compared to vehicle alone (Figure 11A). TFF1, a well-known E2-inducible 
gene was used as a positive control, with this gene showing a 120-fold increase in levels 
as compared to the vehicle alone at 36h (Figure 11B). Based on these initial results 
experimental conditions were then scaled up proportionally for subsequent 3C analysis.  
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Figure 11. BRCA1 and TFF1 mRNA levels at different time points following 
fulvestrant/E2 stimulation in MCF7 cells. Taqman real-time PCR assays for (A) BRCA1 
(B) TFF1 at corresponding time points. All mRNA levels normalised to -glucuronidase 
(GUS) and expressed as a fold change as compared to the vehicle at each corresponding 
time points. Vehicle was DMSO and was set to 1. Data shown are the mean ± SD from 
two technical replicates. 
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To investigate whether the chromatin interactions between PRE1 and the BRCA1 
promoter are associated with BRCA1 transcriptional induction, we performed 3C analysis 
in 36h E2-treated MCF7 cells. As per previous experiments, we used a PCR bait primer 
located in the Hind III fragment that contains the BRCA1 promoter in combination with 
primers designed to Hind III fragments mapping up to 200kb downstream and 70 kb 
upstream of the BRCA1 promoter (Figure12A). The results showed that the interaction 
frequency between PRE1 and the BRCA1 promoter increased by 6-fold in the presence of 
E2 at a time point when BRCA1 transcription was induced (Figures 12B, D and E). Since 
this increase in interaction frequency between PRE1 and the BRCA1 promoter correlated 
with an increased BRCA1 transcription, this suggests that PRE1 may contain enhancer 
elements of BRCA1 and that the interaction is E2-dependent. Although long-range 
chromatin interactions involving DNA regions upstream of the BRCA1 promoter, were not 
detected in MCF7s grown in normal media, it is possible that under different conditions 
interactions may be detected. We therefore also performed 3C using primer combination 
upstream of BRCA1. However, as seen previously, there were no significant interactions 
detected upstream with the BRCA1 promoter upon E2-treatment (Figure 12C). 
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Figure 12. The BRCA1 promoter:PRE1 interaction is E2-regulated in MCF7 cells. A) 
Schematic diagram of the BRCA1 genomic region and HindIII fragments used for 3C 
analysis. P represents the BRCA1/NBR2 bi-directional promoter. Black vertical lines at the 
bottom indicate HindIII sites, black arrows indicate direction of transcription and black 
blocks indicate exons. The break starts after BRCA1 exon 2 and ends before AARSD1 
exon 1. The grey box represents PRE1. 3C interaction profiles of BRCA1 downstream (B) 
and upstream (C) HindIII fragments following fulvestrant/E2 treatment (red line) or  
fulvestrant/vehicle treatment (black line) in MCF7 cells. Results were derived from three 
pooled biological 3C libraries. Data shown are the mean ± SD from two technical 
replicates. Refer to Appendix for primer sequences. Taqman real-time PCR assays for (D) 
BRCA1 (E) TFF1 at the 36h post E2-induction time point. All mRNA levels were 
normalised to -glucuronidase (GUS) and expressed as a fold change as compared to the 
vehicle. Vehicle was DMSO and was set to 1. Data shown are the mean ± SD from three 
technical replicates. 
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5.3 The long-range chromatin interaction between the BRCA1 promoter and PRE1 
is cell-line specific and independent of ER-status. 
To determine if the 3C interaction profiles observed are specific for MCF7 cells, 3C assays 
were also performed in several other ER+ and ER- cell lines. We first performed 3C in 
T47D cells, as similar to MCF7s, these cells are ER+ and in normal media express 
moderate levels of BRCA1. Interestingly,the 3C interaction profile between the BRCA1 
promoter and HIndIII fragments downstream was significantly different in T47Ds as 
compared to MCF7s (Figure13A, B).The results showed no specific interaction between 
the BRCA1 promoter and PRE1, however there was a frequent interaction with a fragment 
approximately 144kb downstream of the BRCA1 promoter. In contrast, similar to MCF7s, 
the BRCA1 promoter fragment showed no chromatin interactions with HindIII fragments 
upstream of BRCA1 in T47Ds (Figure 13A, C). 
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Figure 13. 3C reveals an additional novel element that interacts with the BRCA1 
promoter in T47D cells. (A) Schematic diagram of the BRCA1 genomic region and 
HindIII fragments used for 3C analysis. P represents the BRCA1/NBR2 bi-directional 
promoter. Black vertical lines at the bottom indicate HindIII sites, black arrows indicate 
direction of transcription and black blocks indicate exons. The break starts after BRCA1 
exon 2 and ends before AARSD1 exon 1 (diagram not drawn to scale). 3C interaction 
profiles of BRCA1 downstream (B) and upstream (C) HindIII fragments in T47D cells. 
Results were derived from three pooled biological 3C libraries. Data shown are the mean ± 
SD from three technical replicates. Refer to Appendix Table 1 for primer sequences.  
 
 
While no interaction was observed between the BRCA1 promoter and PRE1 in T47Ds 
grown in normal media, we hypothesised that perhaps the interaction is only observed 
when BRCA1 transcription is activated by a particular TF. As mentioned previously, T47Ds 
are ER+ and therefore BRCA1 transcription should be induced using E2. We first 
performed a time-course experiment over 24-48h to confirm that BRCA1 levels were 
increased in T47Ds under the same conditions as MCF7s. The results showed that 
BRCA1 expression was not increased at 24 or 36h, and had a minimal 2.5-fold increase 
after 48h of E2 treatment (Figure 14A). As a positive control for E2-treatment we also 
measured TFF1 expression in the same E2-treated samples, and showed a 70 to 110-fold 
increase in TFF1 expression as compared to the the vehicle (Figure 14B). Given the long 
E2-treatment time required to produce a relatively small increase in BRCA1 transcription, 
we decided not to continue with the 3C experiments in T47D cells. 
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Figure 14. BRCA1 and TFF1 mRNA levels at different time points following 
fulvestrant/E2 stimulation in T47D cells. Taqman real-time PCR assays for (A) BRCA1 
(B) TFF1 at corresponding time points. All mRNA levels normailsed to -glucuronidase 
(GUS) and expressed as a fold change as compared to the vehicle at each corresponding 
time points. Vehicle was DMSO and was set to 1. Data shown are the mean ± SD from 
two technical replicates.  
 
 
3C was also performed on four additional cell lines; two ER- breast cancer cell lines; MDA-
MB-231 and CAL51, and two ovarian cancer cell line;s A2780 (ER+) and OVCAR3 (ER-; 
Figure 15). A distinct interaction was observed between the BRCA1 promoter and 
PRE1only in MDA-MB-231s (Figure 15A), which suggests that this interaction is potentially 
ER-independent. Interestingly, both ovarian cell lines had significant interactions at 
another HindIII fragment located 127 kb downstream of the BRCA1 promoter (Figure 15B). 
Taken together, this data suggests that BRCA1 promoter and PRE1 interaction may 
potentially be cell type specific and may not depend on ER status.  
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Figure 15. The BRCA1 promoter:PRE1 interaction is also detected in the ER- MDA-
MB-231 cell line. (A) Schematic diagram of the BRCA1 genomic region and HindIII 
fragments used for 3C analysis. P represents the BRCA1/NBR2 bi-directional promoter. 
Black vertical lines at the bottom indicate HindIII sites, black arrows indicate direction of 
transcription and black blocks indicate exons. The break starts after BRCA1 exon 2 and 
ends before AARSD1 exon 1 (diagram not drawn to scale). 3C interaction profiles of 
BRCA1 downstream in ER- breast cancer cells; MDA-MB-231 and CAL51 cells (B) and 
ovarian cancer cells; A2780 and OVCAR3 (C) Results were derived from three pooled 
biological 3C libraries. Data shown are the mean ± SD from three technical replicates. 
Refer to Appendix Table 1 for primer sequences.  
 
5.4 Bioinformatic analysis indicates that PRE1 contains chromatin features 
indicative of enhancer activity. 
In support of the hypothesis that PRE1 contains functional regulatory elements, 
bioinformatic analysis showed that the region displayed active chromatin features. Using 
available ChIP-seq data from UCSC and ENCODE we show that PRE1 contains a number 
of DNase hypersensitivity regions which are associated with euchromatin (Figure 16). 
Furthermore, strong H3K4Me1 and H3K4Me3 marks were also observed (Figure 16). 
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H3K4Me1 marks are associated with enhancer and promoter regions and H3K4Me3 
marks are associated with promoter regions [224]. These marks span a region within 
PRE1 of approximately 2kb, and suggest that this region contains an enhancer element 
(Figure 16; red box). This element will now be referred to as Putative Regulatory Element 
1 (PRE1). Notably, PRE1 is also highly conserved amongst placental mammal and 
vertebrates. Although not all regulatory elements are highly conserved, conservation 
studies have previously provided clues to finding many regulatory elements [234-236].  
 
 
 
Figure 16. Bioinformatic analysis shows that PRE1 contains active chromatin 
marks. Light green histograms denote ChIP-seq data from Human Mammary Epithelial 
Cells (HMECs; ENCODE). Grey and black boxes denote DNaseI hypersensitivity regions, 
the darker colour denoting greater DNaseI hypersensitivity. Placental mammal 
conservation is compared across mouse, cat, dog, elephant. Vertebrate conservation is 
compared across platypus, chicken and fugu. The putative regulatory element (PRE1) is 
boxed in red. Assembly used is Mar. 2006 (NCBI36/hg18). 
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5.5 Luciferase assays suggest that PRE1 does not directly affect BRCA1 
promoter activity. 
To determine whether PRE1 can directly regulate the BRCA1 promoter, PRE1 was cloned 
into a luciferase reporter vector containing the BRCA1 promoter. However, luciferase 
assays in MCF7s cells suggested that PRE1 had no significant effect on the BRCA1 
promoter activity under these conditions (Figure 17 and Appendix Figure 2). Perhaps 
PRE1 affects the BRCA1 promoter only under specific conditions such as 
fulvestrant/estrogen induction. To investigate if PRE1 has a regulatory effect on additional 
promoters, AARSD1 and SV40 promoter constructs were also included. Interestingly, 
initial assays suggest PRE1 had an inhibitory effect on both the SV40 and the AARSD1 
promoter as promoter activity was reduced by 42% and 33%, respectively. 
 
 
 
Figure 17. Luciferase reporter assays in MCF7 cells suggest PRE1 does not directly 
affect BRCA1 promoter activity. PRE1 was cloned downstream of a BRCA1-, SV40- or 
AARSD1 promoter-driven luciferase reporter. MCF7 cells were transiently transfected with 
each of these constructs and assayed for luciferase activity after 24h. Striped bars 
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represent constructs containing PRE1. Data shown are the mean ± SD from three 
technical replicates.  
 
5.6 The TF c-Myc binds to both PRE1 and the BRCA1 promoter in vivo 
We next wanted to determine which TFs are potentially mediating the interaction between 
the BRCA1 promoter and PRE1. We first used available ChIP-seq data from ENCODE to 
identify TFs that bound to both BRCA1 and PRE1 (Figure 18). While much of this data is 
unvalidated, it did enable us to prioritise two TFs already implicated in BRCA1 
transcriptional regulation, namely c-Myc and JunD. We decided to start with c-Myc, as this 
is a well characterised TF involved in growth, proliferation and differentiation of cells [237-
240]. c-Myc transcription is induced by E2 [182]. Wang et al has shown that both the half-
ERE and AP1 site located 67kb upstream was responsible for c-Myc trans-activation 
instead of the previously reported 116bp ERE at the c-Myc promoter and E2 rapidly 
induced c-Myc mRNA within 30min in MCF7 cells [182, 241]. In this case, ERE-bound ER 
associates with p300/CBP and with JunD and FosB at the AP1 site. ChIP data 
demonstrated that ER, p300/CBP and Pol II were recruited to both the enhancer and 
promoter upon E2 stimulation which suggests the trans-activating ER complex can 
activate c-Myc transcription via intra-chromosomal looping between the enhancer and c-
Myc promoter [182]. Notably, ChIP assays detected JunD and FosB at the enhancer but 
not at the c-Myc promoter; although knockdown of JunD and FosB and deletion of AP1 
sites suggest that these AP1 members are crucial to ER stimulated c-Myc transcription. 
One possibility is that JunD and FosB weakly associate with the c-Myc promoter and these 
weak interactions are lost during the ChIP process. Since both c-Myc and BRCA1 
expression is mediated by ER, it will be interesting to find out if c-Myc is crucial to PRE1 
interaction with the BRCA1 promoter. c-Myc is believed to regulate gene expression by 
binding to E boxes and recruiting histone acetyltransferases (HATs) [242]. Furthermore, a 
recent paper has also shown that c-Myc activates BRCA1 expression through E boxes 
located in its distal promoter [110].  
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Figure 18. Bioinformatic analysis of TF binding at PRE1. Snapshot from UCSC of the 
PRE1 genomic region (GRCh37/hg18) (A) and BRCA1 promoter region (B) showing TF 
binding ChIP-seq data in HMECs. Red circle indicates c-Myc binding. 
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The significance of the ChIP-seq data from ENCODE needed to be validated as it is 
suggestive only (Figure 18A and B). We first sought to determine whether c-Myc binds 
PRE1 in MCF7 cells using ChIP. ChIP primers were designed to a putative E box in PRE1, 
and to the two E boxes in the BRCA1 distal promoter DP1 and DP2, identified by Chen et 
al (Appendix table 3). [110]. Positive control primers were designed to c-Myc binding sites 
in the AP4 intron 1 and the negative control was a non-E box region in BRCA1 exon 11 
located approximately 30kb downstream of BRCA1 TSS. Initial ChIP experiments showed 
no significant difference in intensity of c-Myc and IgG bands and there was only a faint 
band in the AP4 positive control suggesting that there was a technical problem (data not 
shown). The problem was caused by degradation of the c-Myc antibody as Western blot 
analysis failed to detect any bands, even after multiple rounds of optimisation with protein 
amounts and both primary and secondary antibody concentrations. A new vial was 
obtained from Santa Cruz and tested before use in ChIP. Western blotting demonstrated 
that the new vial of c-Myc antibody was functional as there were clear bands observed of 
the correct size (Figure 19).  
 
 
Figure 19. C-Myc antibody optimisation. Cell lysates harvested from MCF7 cells were 
used to test a new c-Myc antibody. 20 or 30ug of protein and 1:5,000 or 1:10,000 primary 
antibody was used for the Western Blot.  
 
Using the new anibody for ChIP, we detected bands for the PRE1 E box, BRCA1 DP1/2 
and AP4 which were significantly darker in the c-Myc lane as compared to IgG, suggesting 
that c-Myc may bind to PRE1, the BRCA1 distal promoter and the positive control AP4 
(Figure 20A). In contrast, there was no difference in intensity between the faint c-Myc and 
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IgG bands in the Non-E box negative control suggesting that there was only a small 
amount of non-specific binding in both c-Myc and IgG samples. It was observed that the 
BRCA1 DP1 showed less binding than BRCA1 DP2 although there is only one base 
different between BRCA1 DP1 and DP2. Since the motif for PRE1 and BRCA1 DP2 is 
similar and both intensities are much darker than BRCA1 DP1, it is possible that the 
difference in binding is due to the one base difference in the binding motif. However this 
would need to be verified by additional experiments. It should be noted that this 
preliminary ChIP data is not quantitative. To examine the degree of conservation between 
the PRE1 E box and BRCA1 DP1 and DP2 E boxes we aligned the DNA sequences 
(Figure 20B). Notably, the PRE1 E box shares high sequence similarity with both DP1 and 
DP2 and to the conventional c-Myc binding E box motif from the JASPAR core database 
(Figure 20C) [243]. Collectively, our data suggests that c-Myc is binding to a loosely 
conserved E-box motif within PRE1 denoted by CACXTX, whereby X can be T or G. 
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Figure 20. c-Myc binds to E boxes in PRE1 and the BRCA1 promoter. (A) ChIP 
assays using anti-c-Myc antibody or control IgG in MCF7 cells. The “Input” lane represents 
the sonicated DNA before antibody treatment. This represents how much material exists at 
the start of the experiment. The “No Antibody” lane represents cross-linked DNA that was 
not incubated with any antibody. The “No DNA” lane represents a PCR negative control 
whereby DNA is replaced by a similar volume of water. A representative figure of two 
biological replicates is shown. (B) Conservation of c-Myc binding sites (E boxes) between 
PRE1 and the BRCA1 distal promoter, bold indicates conserved sequences and 
underlined matches the JASPAR c-Myc binding motif (C) Conventional E box from 
JASPAR core database. 
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5.7 Depletion of c-Myc does not alter the activity of PRE1 or the BRCA1 promoter 
in vitro.  
To examine whether binding of c-Myc at PRE1 alters the regulation of BRCA1, luciferase 
reporter constructs containing the BRCA1 promoter and PRE1 were co-transfected with c-
Myc or control siRNA. To optimise siRNA transfection conditions, various time points and 
amounts of siRNA were used (Figure 21). The most effective c-Myc silencing was 
achieved at 72h post-transfection with 100nM of siRNA, which resulted in a 70% reduction 
in c-Myc expression (Figure 21). Optimised c-Myc siRNA was then co-transfected with 
luciferase constructs and RNA extracted 72h post-transfection (Figure 22). The results 
suggest that there was no difference in BRCA1 promoter activity when c-Myc was reduced 
with or without PRE1 (Figure 22B). Again, this results needs to be validated with additional 
biological replicates, however this result was not likely due degradation of total RNA, as 
the quality and quantity of RNA was similar between samples (Figure 22A). Nor was it due 
to inefficient silencing of c-Myc, as qRT-PCR suggested c-Myc expression was reduced by 
70% (Figure 22C) and BRCA1 expression was also reduced by 30% (Figure 22D) for 
samples co-transfected with the same constructs, suggesting that the knockdown was 
successful. Given the role of c-Myc in the transformation of cells is it possible that lack of 
change in activity may be due to a decrease in cell growth. This is preliminary data which 
should be repeated once luciferase experiments have been optimised. 
 
Figure 21. Optimisation of c-Myc siRNA conditions. C-Myc was silenced in MCF7 cells 
using 50nM or 100nM of siRNA, RNA was then harvested at 48h or 72h post-transfection. 
500ng of RNA was reverse transcribed and used for qRT-PCR using c-Myc Taqman probe, 
normalised to GUS. Relative expression for si-Con was set as 1. Data shown are the 
mean ± SD from two technical replicates. 
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Figure 22. Reduction of c-Myc does not alter PRE1s enhancer activity on the BRCA1 
promoter. MCF7 cells were transiently co-transfected with 100nM of c-Myc or control 
siRNA and 600ng of luciferase constructs. (A) Total RNA was harvested 72h post-
transfection and ran on 1% agarose gel. (B) Luciferase activity after 72h. Data shown are 
the mean ± SD from three technical replicates. Taqman real-time PCR assays for (C) c-
Myc and (D) BRCA1, normalised to -glucuronidase (GUS). Data shown are the mean ± 
SD from two technical replicates.  
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6 RESULTS – CHAPTER 2 
6.1 Identification of novel long-range interactions that associate with the BRCA1 
promoter using genome-wide 4C. 
 To identify additional novel long-range interactions that associate with the BRCA1 
promoter, Dr Stacey Edwards performed small-scale 4C in MCF7 cells using a 
combination of BsrGI/NlaIII restriction enzymes and inverse primers specific for the 
BRCA1 promoter (Figure 8, unpublished data). As this was only a small-scale 4C 
experiment, in lieu of next-generation sequencing, 4C PCR products were instead shotgun 
cloned into pGEM-T Easy (Promega). One hundred random clones were then sequenced 
at Macrogen (Korea) and the resulting sequencing data compared to the human genome 
using NCBI (http://www.ncbi.nlm.nih.gov/). As part of my project, the four best candidate 
inter-chromosomal interacting regions from this screen were chosen for validation by 3C. 
These candidate genes were; NCDN (Neurochondrin) [244], MDK (Midkine) [245],PXN 
(Paxillin) [246] and G2E3 (G2/M-phase specific E3 ubiquitin protein ligase) [247, 248]. 
These four genes were chosen as the interacting fragment was very close to or within a 
gene already associated with breast cancer (Table 2).  
 
Nearest  
Gene 
Name 
Location/ 
distance 
from gene 
No. clones 
sequenced 
( /100) 
Associated with breast cancer? Ref/s 
NCDN 
(Chr1) 
 
Intron 3 2 Involved in signal transduction, 
associated with breast cancer 
[244] 
[249] 
[250] 
MDK 
(Chr11) 
 
7kb 
upstream 
4 Promotes 
angiogenesis,expressioncorrelated 
with lymph node metastasis 
[251] 
[252] 
PXN 
(Chr12) 
 
5’UTR 1 Overexpressed in metastatic 
breast tumours and associated 
with estrogen stimulated cellular 
migration in T47D 
[253] 
[254] 
G2E3 
(Chr14) 
 
5kb 
upstream 
4 Ubiquitin ligase, nucleo-
cytoplasmic shuttling protein 
involved in DNA repair 
[247, 
248] 
Table 2. List of prioritised BRCA1 promoter interacting regions identified by a small-
scale 4C experiment in MCF7 cells. 
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6.2 A putative regulatory element located 5kb upstream of G2E3 physically 
interacts with the BRCA1 promoter. 
To validate the 4C-identified interactions, 3C libraries were generated from MCF7 cells 
using HindIII. The PCR bait primer located in the HindIII fragment that contains the BRCA1 
promoter was used in combination with primers designed to three adjacent HindIII 
fragments, upstream (Up), middle (M) and downstream (Dn) that cover each of the four 
regions (Figure 23). Excitingly, a specific interaction was detected with the G2E3 
downstream region (Figure 23). Bioinformatic analysis of this 1.66kb HindIII fragment 
shows that it contained a DNase I hypersensitive peak and a strong H3K4Me1 mark 
suggesting that it could be an enhancer element (Figure 24A). Figure 24B also shows 2 
transcription factors CEBPB and Fos which are also found on the BRCA1 promoter (Figure 
18B). This fragment is the first reported inter-chromosomal interaction with the BRCA1 
promoter. There were no interactions detected with the other three candidate genes in this 
library therefore they were deprioritised from experiments. The interacting region, which 
will now be referred to as PRE2 Fragment1 (F1), containing the 1.66kb fragment was then 
cloned into BRCA1 promoter constructs for luciferase assays. 
 
 
 
 
Figure 23. A region upstream of G2E3 interacts with the BRCA1 promoter in MCF7 
cells. Agarose gel electrophoresis of PCR products amplified from a HindIII 3C library. 
Primers were designed to three adjacent fragments; upstream (Up), middle (M) and 
downstream (Dn), that covers each of the four regions shown to interact with the BRCA1 
promoter by 4C.  
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Figure 24. Bioinformatic analysis of upstream G2E3 interacting fragment. A) Modified 
snapshot from UCSC of Chr 14: 31,016,644-31,032,422 (GRCh37/hg19) showing the 
location of PRE2 F1 (red box), F2 (green dashed box) and F3 (blue dashed box) upstream 
of G3E3. Light blue solid boxes are DNase hypersensitivity clusters and pink histograms 
are histone marks in HMECs. B) Modified snapshot from UCSC of chr14:31,018,616-
31,030,450 (GRCh37/hg19) showing the corresponding TF binding around PRE2. TFs 
circled in blue also correspond to TF binding at BRCA1 promoter (refer to Figure 18B). 
 
6.3 PRE2 enhances G2E3 but has no effect on BRCA1 promoter activity in vitro.  
To determine whether PRE2F1 can directly regulate BRCA1or G2E3 promoter activity, 
PRE2 F1 was inserted into luciferase reporter vectors containing either the BRCA1 or 
G2E3 promoters. Using luciferase assays in MCF7s cells we demonstrated that PRE2 F1 
A 
B 
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acts as a strong enhancer of G2E3, resulting in a 3.44 fold increase in G2E3 promoter 
activity (Figure 25). In contrast, there was no significant change when PRE2 F1 was 
introduced in a luciferase reporter construct containing the BRCA1 promoter (Figure 25). 
As the BRCA1 promoter is a bi-directional promoter, PRE2 F1 was also cloned into a 
construct containing the BRCA1 promoter in the reverse direction, so as to drive NBR2 
expression. Similarly, PRE2 F1 had little effect on the NBR2 promoter; there was only 
approximately 18% drop in relative luciferase units and the standard deviation was large 
(Figure 25). Therefore, it is possible that PRE2 F1 is only a very weak silencer for NBR 
promoter. Perhaps this PRE2 F1 can act as an enhancer or silencer, depending on the 
promoter in question. There are a number of possibilities, as to why PRE2 F1 had no 
effect on the BRCA1 promoter activity. Firstly, the PRE2 F1 region cloned could be too 
small and not include all the relevant regulatory elements. Secondly, the BRCA1 promoter 
region could also be too small and the TF binding required for transactivation might lie 
outside the minimal 500bp BRCA1 promoter fragment that was cloned. Thirdly, the 
interaction could be non-functional under these experimental conditions. 
 
 
 
Figure 25. PRE2 enhancers G2E3 but not BRCA1 or NBR2 promoter activities. 
Luciferase reporter assays in MCF7 cells. PRE2 was cloned downstream of a G2E3, 
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BRCA1 or NBR2 promoter-driven luciferase reporter and assayed for luciferase activity 
after 24h. Data shown are the mean ± SD from three technical replicates. Striped bars 
represent constructs containing PRE1.  
 
In an attempt to address some of these questions, we cloned two additional larger 
fragments encompassing PRE2F1, called PRE2 fragment 2 (F2) and enhancer 3 (Figure 
24; blue and green dashed boxes). PRE2 F2 is 3.172 kb and PRE2 F3 is 4.442 kb. Both of 
these new DNA fragments were cloned downstream of the BRCA1 promoter and assayed 
for luciferase in MCF7 cells. Interestingly, initial reporter assays suggest that both PRE2F2 
and F3 constructs can decrease BRCA1 promoter activity, resulting in a 2- and 3-fold 
decrease in activity, respectively (Figure 26). This very exciting result suggests that our 
hypothesis was correct in that we had not included all the necessary regulatory elements 
in the original PRE1 F1 construct. It also provides preliminary evidence that PRE2 can act 
as a silencer of BRCA1 transcription.  
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Figure 26. Larger G2E3 enhancer constructs can repress BRCA1 promoter activity. 
Luciferase reporter assays in MCF7 cells. Two additional PRE2 regions were cloned 
downstream of the BRCA1 promoter-driven luciferase reporter and assayed for luciferase 
activity after 24h. Data shown are the mean ± SD from three technical replicates.  
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7 DISCUSSION 
7.1 Overview 
 
BRCA1 plays an important role in breast cancer susceptibility; however the molecular 
mechanisms controlling its expression are only partly understood. In this report we show 
that the BRCA1 promoter interacts frequently with a DNA region approximately 157kb 
downstream. This long-range chromatin interaction was observed in MCF7 and MDA-MB-
231 breast cancer cells but not in T47D or CAL51 or ovarian cell lines OVCAR3 and 
A2780, which suggests it may be cell-line dependent. In addition, there was no clear 
correlation between this interaction and reported BRCA1 mRNA levels in MCF7, T47D and 
CAL51 cell lines suggesting that BRCA1 promoter regulation is complex, likely involving 
several mechanisms [72].  
 
The BRCA1 promoter region has been reported to be more methylated in the breast 
cancer cell line, MCF7 than in normal breast cell line such as HMEC (Figure 27A and B) 
and this has been correlated to lower BRCA1 expression [255]. Aside from promoter 
methylation, methylation of other regions can also affect BRCA1 expression. Initial 
attempts by others to identify cancer associated long-range regulatory regions, explored 
evolutionary conserved elements, surrounding the gene of interest, that coincide with 
DNase hypersensitivity regions and tested for functionality using reporter assays as in the 
case for spleen focus forming virus (SFFV) proviral integration oncogene (SFPI1) which 
codes for the transcription factor, PU.1. These procedures were combined with genomic 
bisulfite sequencing or methylation specific PCR to identify DNA methylation-associated 
long range epigenetic silencing (LRES). In myeloma cell lines, both the SFPI1 promoter 
and the SFPI1 enhancer located 17-kb 5′ upstream were highly methylated resulting in 
SFPI1 silencing that is associated with cancer of plasma cells [256-258]. This 
demonstrates long-range transcription repression can occur in cases whereby both 
promoter and long-range regulatory element are methylated, without genetic changes to 
the promoter or regulatory element. In addition, LRES can also occur when CpG 
methylation of long chromosomal regions leads to transcriptional repression not only of 
hypermethylated genes but also of distal unmethylated genes, lying either within or on the 
boundaries of silenced domain [259]. A 4Mb-sized region located at chr2q14.2 has been 
found to be commonly hypermethylated in colorectal cancer through global methylation 
screening [260]. DNA hypermethylation found in three distinct genes namely EN1 
(engrailed 1), SCTR (secretin receptor), and INHBB (inhibin b), has been correlated to 
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transcriptional repression of distal unmethylated genes such as DDX18 (DEAD (Asp-Glu-
Ala-Asp) box polypeptide 18), INSIG2 (insulin induced protein 2), TSN (translin), PTPN4 
(protein tyrosine phosphatase, non-receptor type 4) and RALB (RAS-like protein B) 
located more than 1kb away from the hypermethylated genes [260]. qRT-PCR analysis of 
reverse transcribed RNA revealed that this repression of unmethylated genes was 
abrogated by treatment with DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine, 
combined with HDAC inhibitor, trichostatin A and ChIP demonstrated the same treatment 
combination inhibited repressive H3K9me2 binding at these promoters [260]. Taken 
together, the data suggests LRES occurs through heterochromatinization However in this 
study, it was not clear if transcription repression of unmethylated genes is caused by 
methylation of the three regions (EN1, SCTR and INHBB) collectively or if methylation of 
one of these three genes is enough to induce repression. Perhaps repression of each 
unmethylated gene is dependent on a different combination of methylated genes.  
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Figure 27. High resolution 5-methylcytosine map of the BRCA1 5’ region shows 
MCF7 has more methylation at the BRCA1 promoter than HMEC. Methylation map of 
BRCA1 promoter from A) +16 to +255 and B) -1351 to +17. Normal human mammary 
epithelial cells (HMEC) are from Clonetics and MCF7 are from American Type Culture 
Collection. The numbers are referenced to the BRCA1 TSS. The red box show regions of 
MCF7 demonstrate higher promoter methylation than HMEC. The blue box mark regions 
that show methylation in MCF7 but not HMEC. Adapted from [265] and [105] for Figure 
27A and B respectively. 
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7.2 Discussion – Chapter 1 
In this project, we investigated potential regulatory elements of BRCA1 promoter through 
3C and 4C. The first section will discuss techniques and results derived from 3C. To obtain 
the interaction frequencies for 3C, three biological replicates were pooled prior to qRT 
PCR because the DNA obtained from each sample is very low, often below 100ng/ul, 
sometimes as low as 30ng/ul. This is due to the whole 3C procedure being a very long one 
with multiple enzymatic digestions and washes. Due to the large number of primers used 
for interrogating the regions of interest, we needed a large volume therefore pooling the 
samples was necessary. To completely dissolve the DNA pellet, at least 100ul of 10 mM 
Tris was needed however the yield is usually low. We are also limited by the volume we 
can add to the qRT PCR mixture. Using any volume above 2ul to the PCR mixture inhibits 
the reaction and results in inconsistent results between technical replicates. Perhaps this 
could be due to some impurities remaining in the sample even after phenol-chloroform 
purification or salt in the buffer. One potential limitation of pooling the replicates is that if 
one sample had abnormally high interaction, which was not present in the other samples, 
this would still be seen as a strong interaction in the final result, but would not actually be 
biologically relevant. Furthermore, the 3C experiments have been repeated on different 
occasions with similar results. Figure 9B and Appendix Figure 1B were generated from 
different pooled library samples, which makes them biological repeats. Dr Juliet French 
repeated my experiment on a different batch of library, and obtained the same strong peak 
at position 38374535, similar to Fig 9B and Appendix Figure 1B (Data not shown). The 
interaction frequency in Appendix Figure 1B has approximately doubled for both 
interactions at 38374535 and 38404028 as compared to Figure 9. This could be due a 
higher digestion or ligation efficiency during 3C library preparation or different passage 
number as different passage number has different expression profiles [261]. Importantly, 
we saw consistent strong BRCA1 promoter interaction with DNA fragments containing 
PRE1 across different biological replicates and different 3C experiments with different 
enzymes such as HindIII (Figure 9B and Appendix Figure 1B) and NcoI (Figure 10B and 
Appendix Figure 4). Unexpectedly in Appendix Figure 4, 3C suggested there were almost 
no background interaction with BRCA1 promoter, aside from position 38362979 and our 
region of interest, position 38375848. This could be due to DNA degradation or TF 
degradation during 3C. The repeat experiment (Figure 10B) showed background 
interactions with the BRCA1 promoter and also showed strong interaction at position 
38375848, which contained PRE1 hence the data suggests that PRE1 is truly interacting 
with the BRCA1 promoter. Although both position 38375848 and position 38362979 were 
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detected from biological replicates of the NcoI 3C libraries, we decided to focus on position 
38375848 as only this interaction was strongly detected by both HindIII and NcoI 3C 
libraries. 
 
For 3C, prevention of protein degradation is crucial, as it will determine whether qRT PCR 
can pick up on the interactions at the BRCA1 promoter. If the protein degrades before the 
ligation process, the ligation will not be successful hence there will be no DNA template for 
the BRCA1 promoter bait and interrogating primers to amplify. Therefore protease 
inhibitors have been added to reduce protein degradation and samples were kept on ice 
when possible. Besides protein degradation, estrogen induction of BRCA1 posed another 
problem. Initially for the estrogen induction of BRCA1, there was minimal increase of 
BRCA1 transcription (2 fold or less) upon E2 stimulation. We hypothesised that a 
substantial fold increase upon E2 stimulation will be required when performing 3C as this 
will theoretically result in a larger difference in interaction frequencies between non-E2 and 
E2 treated cells. Previous reports have shown that fulvestrant when combined with 
estrogen can induce cell cycle related cyclin 2 and cyclin 4, and is therefore likely to exert 
the same effect on cell cycle regulated BRCA1 [262]. Interestingly, we found that ER 
specific antagonist fulvestrant is able to further induce BRCA1 transcription when added 
prior to estrogen treatment. Fulvestrant is an ER specific antagonist, which down-regulates 
as well as promotes ER degradation [263, 264]. The exact mechanism of how fulvestrant 
can sensitize ER to estrogen is not known. One possibility is that fulvestrant alters the 
regulation of other genes which enhance ER sensitivity [265]. Since there are two classes 
of ER; the classical ER α/β and the G Protein-coupled ER [266], another possibility is that 
fulvestrant might act on G Protein-coupled ER instead of the classical ER. Importantly, 
fulvestrant was always also added to the vehicle cells in our experiments.  
 
A point to note is that there seems to be a difference in BRCA1 and TFF1 expression 
between the vehicle and E2 treated cells at time 0 in the time-course fulvestrant/E2 
experiments (Fig 11A). Since time 0 signifies no treatment, it was expected that there 
would not be a significant difference. One possibility for this discrepancy is the RNA or 
DNA sample had some residual proteins which interfered with the subsequent reactions. 
However this difference is less than 1 fold which is considered minimal as compared to the 
12.5 and 120 fold increase observed for BRCA1 and TFF1 expression respectively at 
36hr.  
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For Figure 12B, the peak at 38374535 is interpreted as increasing 6-fold in the presence of 
E2 compared to the vehicle cells. However, the E2-treated cells in this figure show an 
interaction which is the same magnitude as that presented in Appendix Figure 1, which is 
derived from MCF-7 cells with no E2 treatment or BRCA1 expression induction. This is 
most likely due to an increase in this interaction due to E2 treatment, and not just 
variability in the assay. The set of data from Figure 12B was performed at separate times 
as compared to Appendix Figure 1B. Therefore what should be compared is the interaction 
frequency increase in the presence of E2 compared to the vehicle cells within the 
experiment, not across data from a separate 3C experiment that uses a different passage 
number of cells, batch of enzymes, reagents and treatment.  Variability is also observed in 
mRNA levels. Figure 12D and 12E suggested approximately 17 fold and 339 fold increase 
in BRCA1 and TFF1 mRNA upon estrogen stimulation respectively however a biological 
repeat (Appendix Figure 5) suggested 24 fold and 440 fold respectively. Such variability is 
may be attributed to cell number or reagent batch differences. It is considered acceptable 
since the fold change of BRCA1 mRNA does not fall below 10 fold, which is our minimal 
target as we hypothesize that a large fold change in expression would be easier to detect 
via 3C.  
 
An interesting result that came from the fulvestrant/E2 induction mentioned above is that in 
Figure 12B, the peak at position 38404028 which was previously observed in Appendix 1B 
for untreated MCF7 cells has now been lost and new interactions are seen between 
positions 38436022 and 38455804 in the vehicle sample. We deprioritised interaction at 
positions 38436022 and 38455804 as they were closer to the baseline of random 
interactions which is about 20 in Figure 12B as compared to 38404028. One speculation is 
that slightly altered interaction profiles might arise from cell cycle changes. Since multiple 
genes are regulated differently during different stages of the cell cycle, this might affect the 
interaction profiles, especially since NBR2 and BRCA1 share the same bi-directional 
promoter. Hence interactions observed here might not affect BRCA1 transcription but 
NBR2 transcription. Another possibility is that fulvestrant induced slight changes in 
interaction profile around the BRCA1 promoter. Given that the region at position 38374535 
which houses PRE1 was the only region to show a consistently strong peak it was 
therefore prioritised for further study. Interestingly, interaction at 38374535 is not observed 
in ER+ T47Ds (Figure 13) however there is interaction at position 38381842 instead. 
Perhaps this is due to cell-line specific interactions. Our results also suggest fulvestrant 
and estrogen treatment in T47Ds requires 12h longer to induce a detectable change in 
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BRCA1 expression as compared to MCF7 (Figure 11A and 14A) therefore we prioritised 
study in MCF7. It is reasonable to speculate that different cell lines might have slightly 
different BRCA1 regulatory mechanisms due to different mutations which could affect 
important TF level, affect protein binding and/or affect crucial pathways that have a net 
effect on the BRCA1 promoter. For example, qRT-PCR and immunostaining showed that 
MCF7 contained higher amounts of p53 miRNA and protein than T47D [267]. Since p53 
inhibits activation of BRCA1 promoter by c-Jun/FosB (Figure 5), regulation of BRCA1 
might differ between these two cell lines [104]. Interestingly, the interaction at position 
38374535 which houses PRE1 is also detected in MDA-MB-231 but not observed in 
CAL51 or ovarian cell lines OVCAR3 and A2780 (Figure 15B and C).  
 
We initially performed 3C in the absence of bioinformatic data for two reasons: (i) to 
perform a more unbiased screen for all the regulatory elements that may be interacting 
with the BRCA1 promoter, and (ii) there was limited breast cell line data available at the 
time and regulatory elements are usually tissue specific. Using available data in HMECs, 
Figure 16 shows PRE 1 mapped to a region close to the end of exon 7 of AARSD1 and 
overlaps with a number of DNase hypersensitivity regions which are associated with 
euchromatin and strong H3K4Me1 and H3K4Me3 marks. Collectively this suggests that 
this region contains an regulatory element. H3K4Me1 marks are associated with enhancer 
and promoter regions and H3K4Me3 marks are associated with promoter regions [224]. A 
point to note on Figure 16 is that the UCSC browser shows H3K4me3 bind to regions 
overlapping the end of exon 7 for AARSD1, which is where PRE1 is located. This is 
unexpected because H3K4me3 peaks are usually associated with promoters, not towards 
the end of exons [224]. Since 3C using restriction enzymes such as HindIII and NcoI 
suggest that PRE1 interacts frequently with the BRCA1 promoter (Figure 9B, 10B and 
12B), one speculation is that unknown TF/TFs interact with the BRCA1 promoter, PRE1 
and H3K4me3, forming a transcription complex. This transcription complex might have 
been processed as a whole during CHIP-seq and therefore H3K4me3 was detected at the 
region labelled PRE1. However this is purely speculation, it might also be possible that 
DNA sequences of PRE1 intrinsically have higher binding affinity to H3K4me3 which may 
or may not have a biological function. Electrophoretic mobility shift assay (EMSA) is a well-
known affinity electrophoresis method that can be used to test this hypothesis.  
 
Also, the regions of conservation shown in Fig 16 could be due presence of a well-
conserved regulatory element and/or exon conservation. Since certain exons have been 
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shown to contain regulatory elements, conservation could be present due to both. For 
example human AGT (angiotensinogen) is regulated by an 80bp enhancer element 
located 1,399bp downstream from the TSS in exon 5 [268]. Furthermore, the hst (heparin 
binding secretory transforming factor-1) enhancer element resides in exon 3 located 3.5kb 
downstream from the TSS [269]. Analysis of not only BRCA1 expression, but also 
AARSD1 expression would have helped to clarify the biological role of PRE1. However it 
was not possible to address the role of AARSD1 experimentally due to time constraints. It 
would be interesting to find out if PRE1 has any biological effect on AARSD1 in addition to 
BRCA1 since PRE1 is located within ARRSD1. Since higher interaction frequency 
between PRE1 and the BRCA1 promoter was shown to correlate with stimulated BRCA1 
transcription during E2 treatment (Figure 15). This raises the possibility that a regulatory 
element residing within this region may be responsible for the up-regulation of BRCA1 
upon E2 induction. To investigate the ability of PRE1 to transactivate BRCA1, PRE1 was 
cloned into BRCA1 promoter constructs for luciferase assays (Figure 17). 
 
Although the inclusion of PRE1 suggested approximately 50% difference in the case of 
AARSD1 promoter, data suggest minimal (below 20%) in BRCA1 promoter activity in 
Figure 17. Since the effect on the AARSD1 promoter was considered beyond the scope of 
this project, we just performed a repeat on the BRCA1 promoter. Using a new DNA 
preparation, the repeat did not suggest difference between luciferase constructs containing 
the BRCA1 promoter compared to BRCA1 promoter+PRE1 (Appendix Figure 2). 
Luciferase assays are very sensitive to small changes in conditions and need to be 
reproducible to be reliably interpreted. Hence more repeats of the luciferase experiment 
are required to come to a definitive conclusion in the future. Due to these conflicting 
results, it is not conclusive if PRE1 can modulate BRCA1 promoter activity. It is possible 
that a larger BRCA1 promoter fragment and/or PRE1 fragment is needed to mediate any 
transactivation by PRE1. Indeed, Chen et al showed that the distal BRCA1 promoter 
region is essential for BRCA1 gene activation by c-Myc [110]. Moreover, the chromatin 
interaction was more frequent following E2 stimulation at 36h but not 6h (Figure 12B and 
Appendix 3B), therefore it is possible that all the factors required for transactivation are not 
present without E2 treatment. Potential experiments include cloning larger DNA fragments 
into the luciferase constructs as well as conducting luciferase assays under different 
biological conditions such as in the presence of E2. Alternatively, the interaction between 
PRE1 and the BRCA1 promoter may not be acting as a classical promoter:enhancer 
association. For example, chromatin interactions have been shown to be involved in other 
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biological functions such as scaffolding or insulating. In the chromosome scaffold model, 
chromatin loops are attached to a coiled chromosome core known as the scaffold during 
interphase and metaphase through nuclear matrix attachment regions (MARs) [270-274]. 
Furthermore, in the topological loop model, insulators define the two end-points of a DNA 
region through looping [275, 276]. DNA looping has been suggested to be the mechanism 
of transcriptional insulation for genes such as interferon gamma, homeobox A and 
apolipoprotein [277-279]. However, due to time constraints this problem was not resolved. 
 
Despite of the lack of luciferase data, ChIP-seq data suggested that a number of relevant 
TFs were binding at both PRE1 and the BRCA1 promoter which supports the presence of 
a regulatory element within PRE1 (Figure 18). However since this preliminary ChIP data is 
not quantitative, an improvement could be to repeat this with qRT-PCR. One of these 
candidate TFs was c-Myc. C-Myc is a well-characterised TF and overexpressed in breast 
cancer [280]. A recent paper has also shown that c-Myc activates BRCA1 expression 
through E boxes located in its distal promoter [110]. The c-Myc binding E box motif on the 
JASPAR database (Figure 20C) describes the E box between c-Myc and Max however 
Chen et al describes the E box as E box sequences CACTTG or CACGTT in the case 
where c-Myc activates the BRCA1 promoter [110, 281] (Figure 20C). Hence the primers in 
this project were designed to E boxes described by Chen et al since this project 
investigates c-Myc as a potential TF up-regulating the BRCA1 promoter activity. In the 
Chen et al paper, the binding TF partner of c-Myc was not identified [110]. Dimerization is 
required for c-Myc DNA binding as DNA binding is abolished when the half sites are 
altered [282]. Besides Max, the c-Myc protein can also dimerize with another c-Myc protein 
[283]. In addition, c-Myc can also interact with various proteins such as BINI, MIZ1, PAM, 
TRRAP, Mad and YY1 [284-290]. It is possible that the c-Myc binding E box motif differs 
slightly, depending on the identity of its binding TF partner and/or type of promoter since 
different TF binding partners might affect the three-dimensional structure of the c-Myc 
protein complex and/or the promoter sequence and hence access to E boxes. Protease 
inhibitors have been added and samples were kept on ice during harvest for CHIP (Figure 
20A) to slow down protein degradation. Preliminary CHIP performed using primers 
designed to E boxes suggested that c-Myc did indeed bind to both the BRCA1 promoter 
and PRE1 (Figure 20A). However, in luciferase assays, reduction of c-Myc by siRNA had 
no effect on BRCA1 promoter activity. Again, it is possible that the DNA regions cloned for 
PRE1 and the BRCA1 promoter were not sufficiently large enough to see any effect. 
Unfortunately due to time constraints these experiments were not completed. However, 
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potential experiments could include replacing the PRE1 and BRCA1 promoter with larger 
DNA regions and repeating luciferase assays +/- c-Myc siRNA. Alternatively, c-Myc might 
not be involved in transactivation of BRCA1 but might play a role in looping instead. To 
test this hypothesis, +/- c-Myc knockdown followed by 3C will reveal if the interaction 
profile changes upon reduction of c-Myc.  
 
As BRCA1 mRNA levels and interaction with PRE1 both peaked quite late at 36h of E2 
treatment, it is unlikely that E2 directly stimulates BRCA1 transcription but rather is 
indirectly stimulated through up-regulation of a TF regulating BRCA1. An increase in 
BRCA1 promoter/PRE1 interaction is only observed at 36hr (Figure 12B) but not 6h 
(Appendix Figure 3). This suggests indirect regulation of BRCA1 promoter. For example, if 
c-Myc knockdown coupled with luciferase or 3C shows that c-Myc is involved with 
transactivation and/or looping of PRE1 respectively, it might be the TF involved in indirect 
E2 induction of BRCA1. Since E2 has already been shown to stimulate c-Myc promoter 
activity and increase c-Myc protein levels [182], this might promote interaction of PRE1 
with the BRCA1 promoter, resulting in elevated BRCA1 as a result of indirect E2 
stimulation [182, 291]. If this were the case, c-Myc would be required to be up-regulated 
first, which could explain the delay in detection of an increase in BRCA1 mRNA. It would 
be interesting to perform a time-course of c-Myc and BRCA1 using qRT-PCR in E2 
experiments to investigate if c-Myc levels peak first, followed by BRCA1. Since microarray 
combined with a variety of other methods has demonstrated that E2 regulates many 
genes, another possibility is that transcriptional activation by E2 is the net effect of 
modulation of more than one protein associated with BRCA1 transcription regulation [163, 
292-294]. To test further if c-Myc is involved in BRCA1 regulation by PRE1, c-Myc was 
knocked down by siRNA. 
 
With regards to the siRNA experiments, I acknowledge that performing a Western blot 
would provide a better check in addition to scrutinizing mRNA levels since degradation of 
the protein is the main aim of the c-Myc knockdown experiments. Western blot was 
optimised for c-Myc (Figure 19) to test if knockdown by si-RNA is successful but only 
mRNA levels could be checked due to time constraints. However in the absence of the 
Western Blot, I am assuming that c-Myc knockdown is efficient since there was 
approximately 70% reduction in c-Myc mRNA with 100nM of si c-Myc at 72hr (Figure 21) 
and half-life of c-Myc is short. The half-life of c-Myc is 20-30mins. 
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For Figure 21 and 22C and D, β-Glucuronidase (GUS) was used as an endogenous 
control for Taqman qRT-PCR to obtain fold change for BRCA1 and TFF1 mRNA and to 
account for differences due to the siRNA. As it has been reported that GUS has low 
variation across peripheral blood samples extracted from 17 individuals and is stably 
expressed across 16 different tissues 
(http://tools.invitrogen.com/content/sfs/brochures/cms_042279.pdf). In addition, another 
report revealed that GUS showed low variability across 6 different cell lines [295]. 
Furthermore, GUS has been previously used as an housekeeping control for investigating 
the effects of Fulvestrant on expression of ER target genes in four human breast cancer 
cell lines, including T47D and MCF7 [296]. GUS is therefore an ideal house-keeping gene 
for detecting increased BRCA1 mRNA levels induced by Fulvestrant-E2 in different cell 
lines. In Figure 22C and 22D, GUS was also used in qRT-PCR after siRNA treatment. The 
average and standard deviation has been added in Appendix Table 4. It is not known if the 
siRNA treatment can affect GUS expression. To confirm that results are not confounded 
by irregularities caused by the housekeeping gene, an improvement would be to include 
more than one endogenous control. 
 
Including an untreated control will demonstrate if the siRNA control exerts any effect on c-
Myc or BRCA1 expression by itself since even siRNA controls have been reported to 
induce off targets effects in different cell lines [297]. For example 2 out of 13 siRNA 
controls tested, decreased NFKappa β signalling in human fibroblast cells [297]. Hence, it 
is possible that the control siRNA may have an off-target effect which could change the 
expression of c-Myc/BRCA1 or genes regulating c-Myc/BRCA1, and if so will confound the 
interpretation of the results. There also have been reports of off-target effects of siRNAs, 
aside from the siRNA control [298]. For example, siRNA transfection is associated with the 
non-specific induction of inflammatory cytokines and type I interferon via crosstalk 
between RIG-I and IFI16 signalling pathway [299]. Also from experience, different 
transfection reagents exert varying degrees of cytotoxicity in different cells lines and may 
affect gene expression by themselves. An improvement would be to include a control of 
cells treated with all reagents, including the lipofectamine, but without any siRNAs to 
detect any effects from the transfection reagents. Since siRNA activates the RNA-induced 
silencing complex (RISC), an additional positive control such as si GAPDH, will 
demonstrate that activation of the RISC signalling pathway does not affect expression of 
the genes of interest. Also, since it is not always the case that siRNA induced reduction in 
RNA level correlates to a reduction in protein levels, it is important to relate reduction of 
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RNA to reduced protein expression by Western Blot before publishing a paper based on 
these results [300]. This is especially crucial if the intent is to knockdown a protein such as 
c-Myc with siRNA followed by 3C or 4C as conformation capture to observe if there are 
changes in interaction frequency since 3C and 4C are expensive to perform.  
 
Since c-Myc is a TF that regulates many genes that directly or indirectly affect growth or 
viability, the c-Myc knockdown data needs to be expressed relative to cell count, should 
this experiment be carried out. Differences in cell count, if any, can be detected with cell 
viability assays such as CellTiter-Glo (Promega). Since the si RNA data (Figure 22C and 
D) presented only shows mRNA knockdown but not the c-Myc protein itself and there was 
no si GAPDH control and cell viability assays performed, Figure 22 should be only 
regarded as preliminary data. Figure 22B suggests that reduction of c-Myc does not alter 
PRE1 enhancer activity on BRCA1 promoter as there was no observable difference with or 
without c-Myc knockdown in the case of B1 prom+PRE1. Unexpectedly in Figure 22B, the 
BRCA1 prom+PRE1 construct shows an increase when compared to the BRCA1 promoter 
only construct, even in the presence of the control siRNA. It is possible that the control 
siRNA may have an off-target effect which could change the expression of c-Myc or genes 
regulating c-Myc, and if so will confound the interpretation of the results. siRNA c-Myc 
experiments should be repeated if optimised luciferase assays show PRE1 has an effect 
on BRCA1 promoter.  
 
Clearly, if the results show that c-Myc is not involved in loop formation or transactivation of 
BRCA1 promoter, it will be necessary to investigate the role of another TF. Another 
potential candidate is Jun-D as ChIP-seq data from the UCSC browser suggested that 
Jun-D binds to both the BRCA1 promoter and PRE1 (Figure 18). Moreover, Jun-D mRNA 
levels increase upon E2 treatment [301] and JunD binds weakly to ER [302], suggesting 
that it might be involved in E2 regulation. Members of Jun and Fos families can dimerize to 
form AP1, and this complex has been associated with E2-stimulated BRCA1 transcription 
[104, 303, 304]. Therefore, Jun-D would be a suitable TF candidate for ChIP and siRNA 
knockdown assays. For knockdown assays, siRNAs against Jun-D could be co-transfected 
with luciferase constructs, with cell lysates and RNA harvested for Western Blot and qRT-
PCR respectively. If reduction of Jun-D alters the effect of PRE1 on BRCA1 promoter 
activity, knockdown coupled with 3C can be performed to investigate if the knockdown 
abolishes BRCA1 promoter interaction with PRE1. One point to note is that data presented 
in Figures 11, 14, 21, 22 and 25 are discussed in the text as preliminary data requiring 
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statistical validation since no definite conclusions can be drawn from one biological 
replicate. 
7.3 Discussion - Chapter 2 
Chapter 2 of this report describes the identification of an inter-chromosomal interaction 
between chromosome 14 and BRCA1 that acts to silence BRCA1 promoter activity. This 
interaction was first identified through a small-scale 4C experiment in MCF7 cells then 
confirmed using 3C. Figure 23 shows the 3C PCR confirmation of the previously identified 
4C interactions stated in Table 2. Although of the four regions interrogated, only the 
upstream region shows a PCR band, the other three regions might still interact with the 
BRCA1 promoter. There are at least two explanations for this. Firstly, TF interactions to 
the BRCA1 promoter and candidate region could be weak and harsh chemical treatments 
during handling of 3C DNA could have abolished this interaction. Secondly, since the 
whole 3C process takes several days in vitro, the TF bridging the interaction between the 
BRCA1 promoter and the candidate region could have degraded although proteinase 
inhibitor was added. Furthermore, this experiment was only carried out once due to time 
limitations and therefore requires verification. As was done for the BRCA1 promoter/PRE1 
element, the ability of the amplicons to detect an interaction between the BRCA1 promoter 
and other three candidate regions can be confirmed by ligating cosmids which cover these 
areas. However due to time constraints, this was not completed. Figure 24 showed 
regulatory element-associated histone marks are present at PRE2 and TFs such as 
CEBPB and Fos are both found at PRE2 and the BRCA1 promoter suggesting PRE2 
might be a regulatory element, 
 
One point to note is that the relative luciferase units for pGL3 base + B1 promoter Figure 
17, 25 and 26 is 70, 4 and 20 RLU respectively. To calculate RLU, the raw firefly luciferase 
readings were divided by Renilla and then multiplied by an arbitrary number to make it a 
whole number for graphing. Results were meant for individual analysis and not to be 
compared across different luciferase assays as differences are expected to arise from 
conditions such as different passage numbers and different batches of Renilla. The Dual 
Glo reagent is expensive and any remainder is always frozen for future use. Results from 
a fresh bottle of Dual Glo and a bottle of freeze-thawed bottle might differ hence variations 
are expected. Also passage number, quality of each batch of DNA is different each time 
and might contribute to variations. Initial cloning of the interacting 1.66 kb DNA fragment 
into the BRCA1 promoter luciferase construct showed that the element acted as an 
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enhancer for G2E3 but not for BRCA1 (Figure 25). One possible explanation was that the 
PRE2 F1 cloned might have been too small and important TF binding sites might lie 
outside of this region. Therefore, two larger DNA regions called PRE2 F2 and PRE2 F3 
were cloned into the BRCA1 promoter construct. Luciferase experiments showed that both 
these elements had a repressive effect on the BRCA1 promoter. PRE2 F2 and PRE2 F3 
constructs decreased BRCA1 promoter activity, resulting in a 2- and 3-fold decrease in 
activity, respectively (Figure 26) Since PRE2 F3, which comprised of a PRE2 F1 and 
PRE2 F2, inhibits BRCA1 promoter more so than PRE2 F3, it suggests that a larger region 
was required for inhibitory action. Figure 26 has only been carried out once due to time 
constraints so further verification is needed. Conventional regulatory elements are usually 
small, however in the case of PRE2, a region of approximately 4kb was required to have a 
strong effect. One possibility could be that enhancer RNAs are involved.  
 
Many studies have implicated non-coding RNAs (ncRNAs) in the regulation of gene 
expression, by affecting mRNA transcription, splicing, export, stability, and translation 
[305, 306]. Of particular relevance to long-range regulation are a recently discovered, 
novel class of non-coding RNAs called enhancer RNAs (eRNAs) [307]. RNA-seq data has 
revealed that over 40% of enhancers are transcribed in murine neurons upon neuronal 
stimulation [308], which positively correlated with gene activation. Furthermore eRNA 
detection was limited to the nucleus which suggests eRNAs involvement in gene activation 
[309]. Taken together, eRNAs seem to be functionally involved in gene transcription, but 
how eRNAs regulate transcription is still unknown. There are three proposed mechanistic 
models [307]. Firstly, eRNAs might be required for activating its corresponding promoter 
since insertion of a terminator sequence between the HS2 enhancer and ε-globin promoter 
resulted in premature termination of eRNA and reduced promoter activity [310]. Secondly, 
eRNAs themselves might promote euchromatin, which in turn favours gene activation. 
Thirdly, eRNAs might be translated to functional proteins but since eRNAs lack 
polyadenylation tails and therefore assumed to be unstable [307], eRNAs might require 
additional modifications before this is possible. Enhancer RNAs are also utilised by 
viruses. For example the viral polymerase IAV (Influenza A Virus) synthesizes small 
regulatory eRNAs that interact within a novel RNA binding channel of the RdRp (RNA-
dependent RNA polymerase) subunit promote polymerase activity in vitro and has been 
suggested to promote genome replication [311]. One possibility is that PRE2 F1 and PRE2 
F2 by themselves are insufficient to elicit an inhibitory effect comparable to PRE F3 
because the enhancer RNA transcribed from PRE2 F1 and F2 is truncated and therefore 
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not fully functional. However it is still unknown if eRNAs exist for the BRCA1 promoter so 
this is only a hypothesis. Another possibility is that a longer sequence of PRE2 is required 
because it acts as a platform for other essential TF that contributes to the inhibitory 
transcription complex at the BRCA1 promoter. 
 
This novel finding is the first reported inter-chromosomal interaction for BRCA1. As inter-
chromosomal interactions are not well documented in the literature an important 
confirmatory experiment would be interphase FISH. To perform this experiment, two 
probes corresponding to the BRCA1 and PRE2 loci could be prepared, along with paints 
for chromosome 14 and 17. These probes could then be used on nuclei from MCF7 cells 
and their nuclear position determined by 3D FISH [312]. A positive result would be the 
nuclear co-localisation of the BRCA1 and PRE2 alleles. Furthermore, interphase FISH 
could be performed in various conditions such as +/- E2 treatment. Since BRCA1 and 
G2E3 are both involved in DNA repair, the PRE2 interaction with the BRCA1 promoter 
might also change upon DNA damage [247]. To examine if 3C interaction profiles change 
upon DNA damage, 3C libraries can be generated from MCF7 cells +/- doxorubicin, a DNA 
intercalating agent that induces double stranded DNA breaks or ionising radiation 
treatment [313]. It will also be interesting to investigate luciferase activity of the BRCA1 
promoter with PRE2 +/- E2 and DNA damage treatment. 
 
MCF7 is the breast cancer cell line most commonly used in this thesis however MCF7 
karyotyping was not carried out in this project because it has been performed by other labs 
(Fig 28). Karyotyping with Giemsa staining, FISH or spectral karyotyping can detect 
abnormalities such as translocations, DNA rearrangements, polysomy, monosomy, and 
insertions or deletions which can affect gene regulation and may contribute to disease. 
Translocations can remove/insert regulatory element/elements and/or genes to different 
locations, hence affecting gene expression which might contribute to cancer. For example 
in a rare case of jumping translocation with the MLL (Myeloid/Lymphoid) gene 
rearrangement in acute monoblastic leukemia, SKY (spectral karyotyping) and 
fluorescence in situ hybridization (FISH) showed amplification of the MLL gene after 
translocation to chromosomes 15q, 17q, and 19q [314]. However, correlations are often 
not very clear. For example, Myb expression is highly correlated with MYB FISH 
translocation (75%) however Myb expression is also positive in 46% of cases without MYB 
translocation [315]. Even for the more sensitive of karyotyping method, the lower limit of 
detection by SKY is estimated to be only 6-10 Mb in size” [316]. This suggests even with 
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karyotyping, small regions of translocations might be undetectable. Since karyotyping has 
revealed that MCF7 is a cell line with multiple rearrangements and polysomy; comparing 
interaction frequency of the breast cancer cell lines against the normal population as well 
as breast cancer patients might provide clues as to whether polysomy, translocations 
and/or DNA rearrangements affects long range interaction frequency.  
 
 
Figure 28. SKY Karyotype of MCF7 shows polysomy, multiple translocations and 
rearrangements. 
(http://www.path.cam.ac.uk/~pawefish/BreastCellLineDescriptions/mcf7.htm) 
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8 FUTURE DIRECTIONS 
BRCA1 regulation is clearly very complex. The BRCA1 promoter is already known to be 
regulated by numerous TFs, and by regulatory elements located within or nearby the gene 
however the role of regulatory elements outside BRCA1 has not been investigated. This 
thesis explores the possibility that additional elements outside BRCA1 regulate the BRCA1 
promoter and are targets of disease-associated mutations. Using a combination of 
chromatin conformation techniques, we have identified a cis-element called PRE1 and a 
trans-element called PRE2, which can physically interact with the BRCA1 promoter. As 
discussed above, additional experiments are clearly required to confirm the functionality of 
these elements. However, to fully understand how PRE1 and PRE2 regulate the BRCA1 
promoter, it will be important to identify all the proteins that bind PRE1 and PRE2. This 
could be achieved using a proteomic approach to identify proteins that bind to PRE1, 
PRE2 and the BRCA1 promoter. For example, proteins could be pulled down using 
biotinylated DNA probes that mimic PRE1/PRE2 and the BRCA1 promoter. After several 
washes, bound proteins could be run on a 2D gel and individual bound proteins could be 
identified by mass spectrometry. These experiments could also be performed under 
different physiological conditions such as +/- E2 treatment to identify proteins that 
differentially bound PRE1/PRE2 and the BRCA1 promoter upon estrogen treatment. 
Furthermore, the ChIP followed by PCR performed on PRE1 (Figure 20) is preliminary 
data which does not show exactly how strongly the PRE binds to the BRCA1 promoter, a 
qRT-PCR is required for publication because that will show fold change. 
 
It will also be important to validate the role of PRE1 and PRE2 in vivo and determine 
whether these elements work in a tissue specific manner. This could be done using a 
mouse model whereby PRE1 and PRE2 are deleted through chromosome engineering 
since the murine genome is quite similar to human (reviewed in [317]). Similar experiments 
have already successfully used this technique for investigating association of genetic 
deletions with diseases such as intestinal cancer and Mowat-Wilson Syndrome (MWS) 
[318, 319]. For example, mice carrying a deletion of a Myc enhancer located 500kb 
upstream of Myc was resistant to intestinal cancer induced by APCmin ( Multiple Intestinal 
Neoplasia) mutation, suggesting that the deletion is responsible for the disease [318]. 
Furthermore, rats carrying enhancer deletion located 1.2Mb upstream of Zeb2 (zinc finger 
E-box binding homeo box 2) demonstrated male rodents had greater occurrence of kidney 
disorders, similar to MWS in humans [319]. It would then be interesting to determine 
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whether the expression of BRCA1 is ubiquitously altered or only altered in a subset of 
tissues/cells. If deletion of PRE1 or PRE2 had a ubiquitous effect on BRCA1 expression 
then it is conceivable that the embryo may not be viable. If this were the case, a 
conditional knock-out approach using the Cre-Lox system could be undertaken whereby 
PRE1/PRE2 could be deleted in mammary epithelial cells.  
 
As discussed, PRE2 was identified through a small-scale 4C approach. This approach is 
limited due to the fact that only 100 random clones were sequenced which would not 
represent all chromatin interactions within the 4C library. It will therefore be important to 
sequence all interactions involving the BRCA1 promoter using a next generation 
sequencing (NGS) strategy. Large-scale sequencing will generate more quantitative 
results as the frequency of the interactions can be calculated based on the number of tags 
sequenced. The coupling of 4C with next generation sequencing is also known as 4C-seq 
and has already been successfully used for a number of different genes including, the 
discovery of an enhancer 17kB upstream of Oct 4 and an enhancer 649kb upstream of 
SATB1 [320]. 4C-seq has also been used to demonstrate frequent homologous pairing in 
the case of Kcnq1 (potassium voltage-gated channel, KQT-like subfamily, member 1) 
[321]. 4C libraries could also be generated following BRCA1 transcriptional induction to 
identify dynamic chromatin interactions that correlate with increased BRCA1 expression 
and therefore interactions that might be driving this process. This could be done in MCF7 
cells with and without 36hr of E2 in a similar way that the 3C was performed in this thesis. 
Follow up on new potential regulatory elements could then be achieved through a 
combination of 3C, bioinformatics, luciferase assays and FISH as described above. In 
addition, to understand the true complexity involved in BRCA1 transcriptional regulation, it 
would be interesting to perform 4C NGS in different cell lines such as ER+/- breast and 
ovary cell lines, and under different biological conditions such as +/- treatment with DNA 
damaging agents. This could help determine whether there is a subset of chromatin 
interactions involving the BRCA1 promoter that found in all cell types or whether the 
interactions are completely different between cell lines.  
 
Besides identifying interactions that might have a biological significance, it would also be 
important to determine which trans-acting factors are mediating the interaction, as this may 
have therapeutic implications. A candidate TF would be steroid receptor coactivator (SRC-
3), as SRC-3 can regulate the BRCA1 promoter in Hela cells [322]. Furthermore, available 
ChIP-Seq data shows that it can bind both the BRCA1 promoter and PRE2 F3 in MCF7 
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cells [322]. Therefore, future experiments could either overexpress or knockdown SRC-3 
in MCF7 cells co-transfected with our luciferase constructs. Interestingly, ChIP-seq data 
also showed the interaction profile of SRC-3 varied upon E2 induction [323]. Therefore, E2 
treated luciferase assays (as described above) could also be carried out to determine if E2 
affects BRCA1 promoter activity when PRE2 is included. Furthermore, following 
overexpression or knockdown SRC-3, 3C interaction profiles of 36h E2 treated MCF7 
could be compared to untreated MCF7 cells. Collectively, these experiments could provide 
evidence that SRC-3 is involved in mediating the inter-chromosomal looping.  
A clear translational aspect of this research is to find novel regions of the genome to 
screen to germline mutations. BRCA1 mutations have only been identified in a proportion 
of patients with tumours suggestive of a BRCA1 defect, many of which display reduced 
levels of BRCA1 expression. As mentioned previously, genetic screening for BRCA1 is 
currently restricted to sequencing coding regions and intron/exon boundaries. If PRE1 and 
PRE2 are indeed regulatory elements of BRCA1, mutations within these elements might 
contribute to breast cancer predisposition. It would therefore be worthwhile to screen 
patient samples for mutations within these regions. As a pilot study, we are currently 
screening approximately 700 patient samples for mutations in PRE1 with the results 
expected in mid-2013. These samples were obtained from Breast Cancer Family Registry 
(Breast CFR) and Kathleen Cuningham Foundation Consortium for research into Familial 
Breast cancer (kConFab) and include patients from breast cancer families that have no 
obvious mutation to coding regions of BRCA1 and BRCA2. Screening should be also be 
performed for PRE2 once FISH has confirmed the interaction. However, because of the 
small sample size, it is possible that rare mutations in these regions may not be found 
during this initial screening.  
In addition to rare mutations, it is possible that common SNPs within these regions may 
alter BRCA1 expression. Using UCSC Genome Browser, eight common SNPs were 
identified within PRE1, namely rs568202, rs690664, rs690941, rs690971, rs690979, 
rs190768845, rs141019323 and rs183332356. It would therefore be interesting to test 
these SNPs in luciferase reporter assays in a similar way described in this thesis. 
Furthermore, seven common SNPs were identified within PRE2, namely rs229174, 
rs17348007, rs7153747,rs77065748,rs73258111, rs7152647 and 72666413. These SNPs 
should also be tested in luciferase reporter assays to determine whether these can alter 
the silencer activity of this regulatory element. This will be important as sequence 
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variations within these regulatory elements could contribute to BRCA1 down regulation 
and hence breast cancer predisposition. 
Moreover, there have been a few reports of cancer associated long-range regulation 
identified through chromosome conformation capture-based techniques. For example 3C 
demonstrated interaction of trans-regulatory element located on 6q13 with the CDKN2B 
(cyclin-dependent kinase inhibitor 2B) promoter on Chr 9p21.3 and loss of a copy of this 
enhancer is associated with increased risk of pancreatic cancer risk [324]. However the 
transcription factor mediating this inter-chromosomal looping remains unknown. In 
addition, 3C also demonstrated that a silencer element located 0.5 Mb downstream of 
PVT1 (Pvt1 oncogene) interacts with the PVT1 promoter and genetic mutation within this 
silencer element decrease YY1 (Yin-Yang-1) mediated chromosomal looping resulting in 
up-regulation of PVT1 which contributes to prostate cancer [325]. This demonstrates that 
chromosome conformation capture-based approaches are important in paving the way to 
identify even more novel regulatory elements in other types of cancer in the future. The 
upcoming challenge is to translate all this information to effective prognosis and/or 
interventions to reduce cancer risk and to improve cancer management. 
In summary, this thesis describes the identification of two putative regulatory elements of 
the BRCA1 promoter. PRE1 is located approximately 157 kb downstream from the BRCA1 
promoter and works in cis whereas PRE2 is located on a different chromosome and 
therefore would work in trans. The full characterisation of these putative regulatory 
elements in the future will provide greater insight into the molecular pathways underlying 
the regulation of a key breast cancer susceptibility gene and may lead to the identification 
of new mutation targets that are critical in sporadic and familial breast cancer 
tumourigenesis. The identification of additional regions of the BRCA1 gene susceptible to 
germline mutation that predispose breast cancer development will be of immediate use in 
the clinical management of breast cancer families that have not had their cancer 
predisposition explained in terms of current knowledge and mutation screening methods. 
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10 APPENDICES  
 
 
 
 
 
Appendix Figure 1. Replicate of 3C interaction profiles of BRCA1 downstream 
HindIII fragments in MCF7 cells. (A) Schematic diagram of the BRCA1 genomic region 
and HindIII fragments used for 3C analysis. P represents the BRCA1/NBR2 bi-directional 
promoter. Black vertical lines at the bottom indicate HindIII sites, black arrows indicate 
direction of transcription and black blocks indicate exons. The break starts after BRCA1 
exon 2 and ends before AARSD1 exon 1. The grey box represents PRE1 (diagram not 
drawn to scale). (B) 3C interaction profiles of BRCA1 downstream HindIII fragments in 
MCF7 cells (Biological replicate of Figure 9B). Results were derived from three pooled 
biological 3C libraries. Data shown are the mean ± SD from three technical replicates. 
Refer to Appendix for primer sequences. 
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Appendix Table 1.3C Hind III primer sequences used in 3C. 
 
  
BRCA1 Promoter 
HindIII Bait Primer  
Primer Sequence Genomic 
location Hind III 
fragment (hg18) 
3C BRCA1 promHind tttttcttttcactgccctgtgc 38,524,942 
3C Hind III upstream 
and downstream 
Primer Sequence Genomic 
location Hind III 
fragment (hg18) 
Upstream Frag 2 ggagtttgttcgttcctcccgtctgg 38,533,650 
Upstream Frag 3 gggtgggtgcatgtagggctgaggaattgg 38,540,466 
Upstream Frag 4 caacccagcagctctccatgtcc 38,545,601 
Upstream Frag 6 ctcactcaatagcaggaggtttcatgtttactacc 38,560,100 
Upstream Frag 7 gagtccaacacctctacacagtatgttcaactagg 38,566,401 
Upstream Frag 8 tcaaaacaactagacaggatttccaaaggctgg 38,568,572 
Upstream Frag 9 ctctctctcccaccaaccttctcaacc 38,569,033 
Upstream Frag 10 tgacagacttcacagctatgaaacaacactgc 38,581,390 
Upstream Frag 11 ccagaaggctgagatgggaggattcc 38,584,308 
Upstream Frag 14 agcaatatgccagctgaactggttttctgg 38,584,521 
Downstream Frag 17 tgacaggaaagacacagagcagg 38,455,804 
Downstream Frag 19 gaaaactcctcttcaaccctcagg 38,440,399 
Downstream Frag 20 gggatcccacccaaatttatagc 38,436,022 
Downstream Frag 21 cacctttactgagtgctgactgagg 38,424,678 
Downstream Frag 22 tgagacaaagtctcaatgccacc 38,420,630 
Downstream Frag 23 caggacaggatcggatacgtagc 38,415,716 
Downstream Frag 24 aaaggcagtgtacctcaacacttcc 38,404,028 
Downstream Frag 25 tcctccatcctgcttaatcattagg 38,387,470 
Downstream Frag 26 tcatgtacttcacctcacttgctcc 38,381,842 
Downstream Frag 27 caggaagaaggcataccttgagc 38,381,019 
Downstream Frag 28 gaaatcagaagccctaccagtctacc 38,374,535 
Downstream Frag 29 tgctcaatggcagctacttgc 38,362,165 
Downstream Frag 30 cagtcagatcagactaaggcacacc 38,353,727 
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Appendix Table 2.NcoI primer sequences used in 3C. 
 
 
Appendix Table 3.ChIP primer sequences. 
 
 
 
 
 
 
BRCA1 Promoter 
NcoI Bait Primer 
Primer Sequence Genomic 
location Hind III 
fragment (hg18) 
3C BRCA1 promNco ggatactttcctaacccagagaggccaaagg 38,540,406 
3C NcoIupstream and 
downstream 
Primer Sequence Genomic 
location NcoI 
fragment (hg18) 
Downstream28F1 acacgaccccactattcccatattcctcg 38,390,219 
Downstream28F2 ccttcgtaacctaggacgtgagggcagc 38,386,599 
Downstream28F3 cagccaatattcaatcactcaacaagtcctgc 38,386,076 
Downstream28F5 gtggaaactttggaacatggaccttgaagg 38,379,940 
Downstream28F7 tctatggaccatcaatgtgcagattgttcttcc 38,377,889 
Downstream28F8 ctctgcttaaagctcttcagaggcttcctgtagg 38,375,848 
Downstream28F9 gctcttgtctactgctgtagcctcatctggtgt 38,363,666 
Downstream28F10 gtgtggagcagaggatcatgtggaagc 38,362,979 
   
ChIP primers Primer Sequence  
ChIPcMycPRE F gtgacagttatgcccgagaggtacg   
ChIPcMycPRE R aggaatgagagaataagccccgacc   
ChIPcMycB1exon11F ctgcttgtgaattttctgagacg   
ChIPcMycB1exon11R gctgttctcatgctgtaatgagc   
Positive Control 
ChIP primers 
Primer Sequence Reference 
ChIPcMycAP4int1 F  cgcgacgtttgtaaattgc [326] 
ChIPcMycAP4int1 R ctcagatcccgaggaagga [326] 
ChIPcMycBRCA1F1 aatgcaaagaccgtccgct [110] 
ChIPcMycBRCA1R1 tccacccctcagcccc [110] 
ChIPcMycBRCA1F2 tgaagggctcctccagcac [110] 
ChIPcMycBRCA1R2 tgagggaccgagtgggc [110] 
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Appendix Table 4. GUS CT values for Figure 22. GUS average and standard deviation of 
CT values corresponding to (A) Figure 22C and (B) Figure 22D. 
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Appendix Figure 2. Luciferase reporter assays in MCF7 cells comparing effect of 
PRE1 on BRCA1 promoter. PRE1 was cloned downstream of a BRCA1 promoter-driven 
luciferase reporter. MCF7 cells were transiently transfected with each of these constructs 
and assayed for luciferase activity after 24h. This was performed using a new DNA 
preparation of pGL3Basic+B1 promoter+PRE1. Note that this was a different passage of 
cells from Figure 17. Results were derived from three technical replicates.  
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Appendix Figure 3. The BRCA1 promoter:PRE1 interaction is time dependent upon 
E2 treatment in MCF7 cells. A) Schematic diagram of the BRCA1 genomic region and 
HindIII fragments used for 3C analysis. P represents the BRCA1/NBR2 bi-directional 
promoter. Black vertical lines at the bottom indicate HindIII sites, black arrows indicate 
direction of transcription and black blocks indicate exons. The break starts after BRCA1 
exon 2 and ends before AARSD1 exon 1. The grey box represents PRE1. 3C interaction 
profiles of BRCA1 downstream (B) and upstream (C) HindIII fragments following 6h E2 
treatment (red line) or vehicle treatment (black line) in MCF7 cells. Results were derived 
from three pooled biological 3C libraries. Data shown are the mean ± SD from three 
technical replicates. Refer to Appendix for primer sequences.  
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Appendix Figure 4. 3C confirms that PRE1 interact with the BRCA1 promoter in 
MCF7 cells. (A) Schematic diagram of the BRCA1 genomic region and NcoI fragments 
used for 3C analysis. P represents the BRCA1/NBR2 bi-directional promoter. Black vertical 
lines at the bottom indicate NcoI sites, black arrows indicate direction of transcription and 
black blocks indicate exons. The break starts after BRCA1 exon 1b and ends before 
RUNDC1 exon 1. The grey highlighted region represents the NcoI fragment that overlaps 
with PRE1 (diagram not drawn to scale). (B) 3C interaction profile of NcoI fragments in 
MCF7 cells (Biological repeat of Figure 10). Results were derived from three pooled 
biological 3C libraries. Error bars represent SD of three technical replicates. Refer to 
Appendix Table 2 for primer sequences. 
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Appendix Figure 5. The BRCA1 promoter:PRE1 interaction is E2-regulated in MCF7 
cells. Taqman real-time PCR assays for (A) BRCA1 (B) TFF1 at the 36h post E2-
induction time point (Biological repeat for Figure 12D and E). All mRNA levels were 
normalised to -glucuronidase (GUS) and expressed as a fold change as compared to the 
vehicle. Vehicle was DMSO and was set to 1. Data shown are the mean ± SD from three 
technical replicates.  
 
 
